MECHANISMS OF PIN1 REGULATION OF IRAK-M STABILITY IN TLR/IL-1R SIGNALING AND STRUCTURE DETERMINATION OF IRAK-M DEATH DOMAIN by Kwon, Jeahoo
  
 
MECHANISMS OF PIN1 REGULATION OF IRAK-M STABILITY IN TLR/IL-
1R SIGNALING AND STRUCTURE DETERMINATION OF IRAK-M DEATH 
DOMAIN 
 
 
 
 
 
 
 
A Dissertation 
Presented to the Faculty of the Graduate School 
of Cornell University 
In Partial Fulfillment of the Requirements for the Degree of 
Doctor of Philosophy 
 
 
 
 
 
by 
Jeahoo Kwon 
August 2018
  
 
 
 
 
 
 
 
 
 
 
 
© 2018 Jeahoo Kwon 
ALL RIGHTS RESERVED
  
MECHANISMS OF PIN1 REGULATION OF IRAK-M STABILITY IN TLR/IL-1R 
SIGNALING AND STRUCTURE DETERMINATION OF IRAK-M DEATH 
DOMAIN 
 
Jeahoo Kwon, Ph. D. 
Cornell University 2018 
 
Asthma is a chronic inflammatory sickness of the airways caused by environmental 
and genetic factors. The mechanisms of activation of the innate immunity signaling 
pathways that cause asthma are not fully understood yet. This study investigated the 
novel targets for the development of new asthma therapeutics. Innate immunity 
provides the first line of defense against bacterial and viral pathogens. Toll-like 
receptors (TLRs) act as sentinels to detect specific pathogen-associated molecular 
patterns (PAMPs). TLR-initiated signaling cascades trigger inflammatory, allergic and 
non-allergic responses via NF-kappaB signaling. Loss of proper innate immunity 
regulation leads to inflammatory diseases such as asthma. IRAK-M is a known 
negative regulator of TLR signaling and is known to assemble into the activated TLR 
signaling complex to attenuate downstream signaling. Prolyl peptide bonds, such as in 
the phosphorylated Ser/Thr-Pro (pS/T-P) motifs recognized by Pin1, can exist in two 
distinct isomer conformations, cis and trans, that exchange on a slow time scale 
(exchange time constant of several minutes). Pin1 can accelerate the isomerization rate 
of pS/T-P motifs by orders of magnitude. The NMR experiments reported here show 
that Pin1 directly interacts with and isomerizes the phosphoS110-P111 peptide bond 
 in a phosphopeptide corresponding to the IRAK-M sequence 103-124 (pIRAK-M), 
and also acts on the corresponding peptide harboring the phosphomimetic mutation 
S110E. Assembly of IRAK-M into the TLR signaling complex is mediated by its N-
terminal death domain. Oligomerization is a hallmark of Death Domains (DD).  The 
IRAKM-DD has eluded structure determination due to aggregation. Here, we report 
the 1H, 13C and 15N backbone and side chain resonance assignments for a double-
mutant IRAK-M Death Domain (R56D, Y61E) that is a highly soluble monomer well 
suited for NMR studies. Furthermore, we solved IRAK-M Death Domain structure 
and simulated docking prediction. 
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Chapter 1 
Background and Overview 
 
Background 
Allergic Asthma 
Allergic asthma is an inflammatory disorder characterized by pulmonary infiltration of 
type 2 T helper cells [1, 2] in response to airborne allergens, house dust mites (HDM), viruses or 
pollen [3], that causes swelling and narrowing of the airways in the lungs. However, asthma 
signaling pathways are still not fully understood and better treatments are constantly under 
development. Asthma is caused by cytokine (IL-4, IL-5, IL-9, and IL-13) and chemokine 
secretion from T-helper type 2 (Th2) cells in lung tissue [4-8]. These cytokines are necessary for 
adaptive TH2 immunity development. The production of type 2 cytokines is regulated by 
upstream signaling pathways, including those initiated by the Toll-like receptor/interleukin-1 
receptor (TLR/IL-1R) superfamily [9, 10] . The activation of such TLRs by airborne allergens 
often induces TH2 response [11] via mediators such as interleukin 33 (IL-33), a ligand for IL-1R 
[12-14]. IL-33 comes mainly from epithelial cells that form the first line of defense against 
inhaled allergens and microorganisms in the lung. IL-33 is secreted to act as both a chemo 
attractant and an immune modulator to activate cells of both the innate and adaptive arms of 
immunity upon stimulation, or as a result of tissue damage. The production of cytokines and 
chemokines is regulated by transcription factors, such as NF-kB, AP-1, GATA and STAT, and 
these transcription factors' activities are elevated in asthma. Also, IL-33 levels are elevated 
compared to healthy individuals or wild-type mice [15]. How these IL-33 signaling pathways are 
regulated, especially after engaging a TLR/IL-1R, is not fully understood. 
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Toll-Like Receptor/interleukin-1 receptor (TLR/IL-1R) Signal pathway in asthma 
Toll-Like Receptors (TLRs) recognize specific molecular markers that are present in 
microbial components, such as viral double-stranded RNA or bacterial lipopolysaccharides, and 
serve as a first line of defense against pathogens [16]. Interleukin-1 Receptors (IL-1R) provide a 
second phase of defense in response to TLR-induced signaling [17, 18]. TLR/IL-1R signaling 
regulates transcription factor NF-kB, which activates gene expression to secrete cytokines. 
TLR/IL1-R family members share structural and functional properties. TLR/IL1-R family 
members activate the same MyD88-dependent pathway to induce an inflammation response [10, 
17].  
Recognition of pathogens by TLR/IL1-R triggers an association with myeloid 
differentiation primary-response protein 88 (MyD88), which recruits IL-1R-associated kinase 4 
(IRAK4). IRAK4 recruits IRAK1 to induce the phosphorylation of IRAK1 kinase domain 
(IRAK1-KD). Phosphorylated IRAK1-KD auto-phosphorylates IRAK1-UD leading to 
recruitment of TRAF6 and to dissociation from IRAK4. The model that IRAK-M prevents the 
formation of IRAK4-IRAK1 or IRAK1-TRAF6 by forming a heterodimer with IRAK-1 and 
binding both MyD88 and TRAF6 was proposed [19, 20]. IRAK1-TRAF6 complex combines 
with transforming-growth factor--activated kinase (TAK1).  TAK1 activation is induced by its 
ubiquitination by TRAF6. TAK1 phosphorylates the IkB kinase (IKK) which phosphorylates 
inhibitor of κB (IκB). NF-κB forms a complex with IκB. When IKK phosphorylates two serine 
residues located in an IκB regulatory domain, IκB is ubiquitinated and NF-κB is released [10]. 
NF-κB activates expression of cytokine genes. Der2, a major HDM allergen, shares structural 
homology with MD-2, which is an LPS-binding component of TLR4 that increases TLR4 
signaling. The inhaled HDM allergens activate TLR4 and induce secretion of various cytokines, 
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including IL-33, IL-25, and GM-CSF, by epithelial cells [14, 21, 22]. HDM also induces a Th2 
cell response by IL-33 mediated promotion of Th2 cell development and stimulation of dendritic 
cells (DCs). The Th2 cell cytokine response promotes the development of allergic inflammation. 
TLR/IL1-R signaling is not only involved in innate immunity but also leads to the development 
of antigen adaptive immunity.  
 
 
 
Myddosome complex 
Toll-Like Receptors (TLRs) transfer the signals to MyD88 and IRAK family through a 
toll-IL-1 receptor (TIL) after TLRs detect microbial components. The crystal structure of the 
death domains [23] complex of the MyD88-IRAK4-IRAK2 was solved [24]. Myddosome 
consists of six of MyD88 DD, four of IRAK4 DD, and four of IRAK2 DD as a left-handed 
helical formation (Figure. 1.2). The DDs of IRAK2, IRAK4, and MyD88 are similar in structure.  
Figure 1.1. TLR/1L-1R signal pathway in asthma 
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IRAK family 
The interleukin-1 receptor-associated kinase (IRAK) family members are important 
signaling mediators of the TLR/IL-1R signaling pathways. In the vertebrate genome, there are 4 
members of the IRAK family: IRAK1, IRAK2, IRAK-M, and IRAK4 [25].  All IRAKs have an 
N-terminal death domain [23] and a kinase domain (KD). IRAK1 and IRAK4 have active 
Ser/Thr kinases, but IRAK-M and IRAK-2 do not have active kinases. IRAK1 and IRAK4 have 
a critical Asp residue (IRAK1 D340, IRAK4 D311) in the kinase domain. However, IRAK2 has 
an Asn residue (IRAK2 N335), and IRAK-M has a Ser residue (IRAKM S293) instead of 
MyD88 DD 
IRAK4 DD 
IRAK2 DD 
Figure 1.2. Myddosome complex 
(3mop) 
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aspartate at this key position in their kinase domain [26]. IRAK-M and IRAK2 are known 
negative regulators of TLR/IL-1R signaling, which is accomplished by binding the MyD88 
adaptor complex [19, 20]. All IRAKs have the linker or the undefined domain (IRAK1) between 
the death domain and the kinase domain. IRAK4 does not have a C-terminal domain. 
 
Death Domain  
The death domain [23] is significantly important in IRAK family binding [24, 27]. The 
DDs of the IRAK family have common amino acid residues which especially have hydrophobic 
side chains such as leucine, isoleucine, and tryptophan (Figure 1.4). In addition, IRAK family 
DDs have commonly charged amino acid residues such as aspartic acid and glutamic acid as 
negatively charged, and arginine as positively charged (Figure 1.4). The DD of IRAK family has 
30 to 39% of similarity (Figure 1.5). The DD of IRAK2, IRAK4, and MyD88 has similar 
structures based on Myddosome crystal structure. The alignment of DDs and phylogenetic tree 
are generated by Clustal Omega (EMBL-EBI, http://www.ebi.ac.uk/Tools/msa/clustalo/)
0 200 400 600 800
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AK
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Figure 1.3. The domains of IRAK family 
members  
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Figure 1.4. The alignment of the death domain of the IRAK family 
 
Figure 1.5. Phylogenetic Tree of the death domain of the IRAK family 
 
 
 Figure 1.6. cis/trans isomers of Pin1 substrates. 
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Pin1 plays important roles in innate immunity 
Peptidyl-prolyl cis/trans isomerase 1 (Pin1) is the only known phosphorylation-specific 
peptidyl- prolyl isomerase in humans. Proline is characterized by its unique ability to exist in two 
conformations: cis and trans (Figure 1.6). Proline cis/trans isomerization is often important as 
the rate-determining step in protein folding [28]. Pin1 catalyzes isomerization of phosphorylated 
S/T-P motifs by reducing the energy barrier of cis/trans conversion [29] (Figure 1.7). Pin1 has 
two domains: an N-terminal WW domain and a C-terminal peptidyl-prolyl isomerase (PPIase) 
domain. The group IV WW domain found in Pin1 binds to phosphorylated S/T-Pro motifs, and 
PPIase domain isomerizes pS/T-Pro sites [30]. Pin1 can regulate protein function in cell 
signaling by controlling protein conformational exchanges upon phosphorylation [31, 32] . A 
Pin1 knockout (Pin1-/-) inhibits HDM-induced pro-inflammatory cytokine production, indicating 
a central role of Pin1 in innate immunity signaling. Pin1 is activated by treating cells with IL-33, 
which activates IL-1R signaling in Th2 cells that induce asthma [14, 33]. Pin1 knockout (Pin1-/-) 
abolishes IRAK1 activation as well as cytokine production in a mouse asthma model [34]. 
 
Figure 1.7. Pin1 reduces energy barrier of cis/trans converstion. 
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Interleukin-33 treatment activates Pin1, and Pin 1 has an important role in asthma 
IL-33 levels are elevated in asthma. Our collaborators have shown that IL-33 stimulation 
activates Pin1 activity and induces asthma [35] . A Pin1-/- showed significant suppression of 
Th2 cell cytokine production and asthma even after IL-33 induction. This data is similar with 
that obtained by inhibiting IL-33 in mouse asthma models [36, 37]. Inhibition of IL-33 results in 
asthma suppression as was observed in the Pin1-/- mouse model [35].  
 
IRAK-M regulates Toll-like receptor signaling.  
IRAK-M is a known negative regulator of Toll-like receptor signaling [19]. There are 
three ways to repress Toll-like receptor signaling. First, IRAK-M associates with IRAK1 to 
prevent IRAK1 dissociation from Mydossome complexes and to prevent the formation of 
IRAK1-TRAF6 complexes [16, 20, 38]. Second, it has been recently found that IRAK-M 
induces inhibitory molecules through TLR7 as part of a second wave of signaling in response to 
endocytosed pathogen [38]. Third, IRAK-M has been shown to inhibit the IRAK2-mediated TLR 
signaling pathway that stabilizes specific mRNAs to promote cytokine and chemokine 
production [17]. Hence, by either blocking or promoting signaling, IRAK-M plays key roles in 
negative regulation of TLR signaling. 
Although its major function appears to be repressive, activation of NF-kB by IRAK-M 
when both IRAK1 and IRAK2 were eliminated has also been reported [35, 39]. In support of 
specific activation roles of IRAK-M, through collaboration we have identified IRAK-M as a 
novel Pin1 target critical for IL-33 signaling in type 2 (TH2) allergic response associated with 
asthma [35]. Briefly, Pin1 is activated in IL-33-induced airway inflammation. Notably, IRAK-M 
is phosphorylated at its S115-P site by IRAK1 upon IL-33 treatment, which induces asthma, and 
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phosphorylated IRAK-M is immune-precipitated by Pin1 antibody [35]. Pin1 binding and 
isomerization of the pS115-P motif increases IRAK-M nuclear translocation and protein stability 
that correlates with increased expression of a set of pro-inflammatroy cytokines that induce 
inflammation. These results were correlated with molecular features of asthma in humans by 
analyzing samples obtained from asthmatic patients challenged with Derp1 (a major allergen of 
house dust mites), where Pin1 activation and IRAK-M levels were increased, and expression of 
the IRAK-M downstream pro-inflammatroy cytokines were increased [35]. 
IRAK-M consists of three domains and a linker: death domain [23], linker, kinase 
domain (UD), and C-terminal domain. pSer110-Pro111 is a potential target site for Pin1 and also 
for TRAF6 (tumour-necrosis-factor receptor-associated factor 6). TRAF6 binds to PxExx(Ar/Ac) 
motifs and the S110-PSEKSY116 motif in lRAK-M linker meets the requirements for a 
canonical TRAF6 binding motif [40]. IRAK-M is expressed in monocytes and macrophages in 
TLR/IL-1 signaling [26] and is also expressed in lung epithelial cells [23]. 
 
Overview  
Quantification of the interaction between phosphorylated IRAK-M and Pin1 
Pin1, which consists of both a WW domain and a PPIase Domain, induces an 
acceleration of the isomerization of pS-P motifs in IRAK-M [3]. Our collaborator’s previous data 
shows that Pin1 binds to IRAK-M tightly as it immuno-precipitates with Pin1. Over expressed 
Pin1 also stabilizes IRAK-M and locates IRAK-M to the nucleus [35]. Pin1 is a pleiotropic 
enzyme, which has multiple effects and interacts with multiple proteins.  The interaction 
between Pin1 and IRAK-M can be direct or indirect. Immunoprecipitation data are consistent 
with a model that Pin1 directly interacts with IRAK-M in vivo [35]. Here we tested the model 
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that Pin1 directly interacts with IRAK-M in vitro by using purified recombinant Pin1 and 
synthetic phosphopeptides, and excluding any other proteins. The dissociation constant KD 
between a phosphopeptide representing IRAK-M residues X-X phosphorylated at S110 (pIRAK-
M) and Pin1 were determined by NMR titration using 1H -15N HSQC spectra. The KD between 
Pin1 and the corresponding peptide with phosphomimetic mutation S110E was also determined. 
The isomerization rate of pS110-P111 in IRAK-M and mutation S110E-P111 in these IRAK-M 
peptides were determined by NMR ROESY experiments. The resulting data, presented in 
Chapter 2, demonstrates a direct in vitro interaction between Pin1 and the IRAK-M sequence 
containing pS110-P111 that we show (in Chapter 4) is solvent-accessible.  These results support 
a model in which Pin1 interacts directly with IRAK-M phosphorylated at S110 in vivo, and the 
retention of Pin1 isomerization of the S110E mutant explains the functional effects of this mutant 
in the mouse asthma model [35]. 
1H, 13C, 15N backbone and side-chain resonance assignment of human R56D, Y61E variant 
of the IRAK-M death domain 
IRAK-M consists of three domains and a linker: death domain [23], linker, kinase 
domain (KD), and C-terminal domain. The association between IRAKs occur through the death 
domain [7].  Even though the role of IRAK-M in Toll-like receptor signaling is significant, the 
mechanism of IRAK-M Death Domain is still veiled. The IRAK-M death domain is not soluble 
in E.coli and rapidly aggregates, precluding the detection of strong NMR signal for each residue. 
Hypothesizing that the observed aggregation was due to the expected oligomerization of the 
death domain, we imparted electrostatic repulsion by mutating suspected oligomer interface 
residues to negatively charged amino acids, producing the double mutant R56D, Y61E.  This 
strategy yielded soluble monomeric IRAK-M death domain. Uniformly 15N-labeled IRAK-M 
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DD (R59D,Y61E) yielded a well dispersed 15N-1H HSQC spectrum, and 13C, 15N-labeled 
protein was subsequently produced. For the first step to unveil the mechanism of the IRAK-M 
death domain, the chemical shifts of IRAK-M death domain were assigned. In Chapter 3, I 
present the backbone and sidechain assignments of a 124- residue consist of IRAK-M [1-119] 
and 5 extra residues at the N-terminal, and identify the secondary structure of the IRAK-M [1-
119] that is consists of 6 α-helices.  
 
Structure determination of human R56D, Y61E variant of the IRAK-M death domain 
Asthma is a chronic inflammatory sickness of the airways caused by environmental and 
genetic factors. The mechanisms of activation of the innate immunity signaling pathways that 
causes asthma are not fully understood yet. This study investigated the novel targets for the 
development of new asthma therapeutics, with a specific focus on IRAKM that is the negative 
regulator within the context of Toll-Like Receptors(TLRs) signaling. Toll-Like Receptors 
(TLRs) recognizes specific molecular markers that are present in microbial components, such as 
viral double-stranded RNA or bacterial lipopolysaccharides, and serve as a first line of defense 
against pathogens. Toll-Like Receptors (TLRs) transfer the signals to MyD88 and IRAK family 
through a toll-IL-1 receptor (TIL) after TLRs detect microbial components. Assembly of IRAK-
M into the TLR signaling complex is mediated by its N-terminal death domain. Oligomerization 
is a hallmark of Death Domains [23].  The IRAKM-DD has eluded structure determination due 
to aggregation. Here, we solved structure of a double-mutant IRAK-M Death Domain (R56D, 
Y61E) that is a highly soluble monomer well suited for NMR studies. Furthermore, we simulated 
possible docking model between IRAK-M DD and IRAK families multi-structures.   
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Chapter 2 
 
Pin1 catalyzes cis/trans isomerization of the pS110-Pro motif in IRAK-M 
Parts of this chapter are published in Nechama, Kwon et al. 2018 (Nechama, M., et al. The 
IL-33-PIN1-IRAK-M axis is critical for type 2 immunity in IL-33-induced allergic airway 
inflammation. Nat Commun 9(1): 1603 (2018)) 
 
Abstract 
Asthma is a chronic inflammatory sickness of the airways caused by environmental and 
genetic factors. The mechanisms of activation of the innate immunity signaling pathways that 
cause asthma are not fully understood yet. This study investigated novel targets for the 
development of new asthma therapeutics, with a specific focus on the peptidyl-prolyl isomerase 
enzyme Pin1 and a key substrate in innate immunity signaling, IRAK-M. Prolyl peptide bonds, 
such as in the phosphorylated Ser/Thr-Pro (pS/T-P) motifs recognized by Pin1, can exist in two 
distinct isomer conformations, cis and trans, that exchange on a slow time scale (exchange time 
constant of several minutes). Pin1 can accelerate the isomerization rate of pS/T-P motifs by 
several orders of magnitude. The NMR experiments reported here show that Pin1 directly 
interacts with and isomerizes the phosphoS110-P111 peptide bond in a phosphopeptide 
corresponding to the IRAK-M sequence 103-124 (pIRAK-M), and also acts on the 
corresponding peptide harboring the phosphomimetic mutation S110E. This study determined 
the dissociation constant, KD, for binding of Pin1 to each of the two peptides by titrating 15N-
labeled Pin1 WW domain with unlabeled peptide and quantifying bound and free populations 
using 1H -15N HSQC spectra. Moreover, the Pin1-catalyzed cis-trans isomerization rates of 
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pS110-P111 and S110E-P111 in these IRAK-M peptides were determined using ROESY 
experiments. These results, together with collaborative biological experiments, implicate the 
Pin1/IRAKM pS110-P111 interaction as critical for dendritic cell activation, type 2 immunity 
and IL-33 induced airway inflammation.  Collectively, these findings offer new therapeutic 
targets for allergic asthma. 
 
Introduction 
The dual domain enzyme Pin1, which consists of a WW domain and a PPIase domain, is 
the only known phosphorylation-specific peptidyl-prolyl isomerase in humans (1, 2). Pin1 
regulates protein function in cell signaling by accelerating the interchange between cis and trans 
conformations of specific pS/T-P motifs (1, 2).  While the PPIase domain catalyzes 
isomerization of substrates, the WW domain is a binding module that typically interacts more 
strongly with the targeted substrates (1, 2).  Interactions between Pin1 and several of its 
substrates are predominantly mediated by the WW domain, with significantly lower affinity 
attributed to the PPIase domain as expected for a classical enzyme (3). 
Our collaborative work with Kun Ping Lu (BIDMC, Harvard Medical School) has shown 
that Pin1 positively regulates the TLR/IL-1R signaling pathway in asthma and is a potential 
therapeutic target in the treatment of immune diseases (4). More recently, the influence of Pin1 
on IL-33 induced immune signaling was found to involve a functional interaction between Pin1 
and IRAK-M.  Our collaborator’s data shows IRAK-M immuno-precipitates with Pin1, that 
over expression of Pin1 stabilizes IRAK-M and locates IRAK-M to the nucleus in dendritic cell 
line DC2.4 (mouse model) when stimulated with IL-33, and that the S110E mutation in IRAK-M 
retains the Pin1-dependent stabilization and localization effects thereby implicating the 
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phosphoS110-P111 site (5). The P111A mutation totally abolished IRAKM phosphorylation and 
Pin1 interaction, which further suggests that proline-directed phosphorylation of this site is 
needed for Pin1 interaction (5). Since Pin1 is a pleiotropic enzyme, with multiple effects 
mediated by interactions with multiple proteins, it is critical to establish whether the observed 
Pin1-dependent effects are due to direct interaction between Pin1 and the phosphoSer110-P111 
site in IRAK-M. Moreover, while immunoprecipitation data are consistent with a model that 
Pin1 directly interacts with IRAK-M in vivo (5), this does not definitively prove a direct 
interaction since a multiprotein complex could be involved.  
The in vitro experiments reported here test for a direct interaction between the isolated 
putative partners, excluding any other proteins. The dissociation constant KD between a 
phosphorylated IRAK-M peptide (IRAK-M residues 103-124 with Ser110 phosphorylated, 
pIRAK-M) and the Pin1 WW domain were determined by NMR titration using the 1H -15N 
HSQC spectrum as a readout. The KD between Pin1 and phosphomimetic mutation IRAK-M 
S110E in the same peptide were also determined. The isomerization rate of pS110-P111 and 
mutation S110E-P111 in these IRAK-M peptides were determined by NMR ROESY 
experiments.  
 
Materials and Methods 
The 15N- labeled Pin1 WW domain (Pin1 residues 1-50) was expressed and purified as described 
(6). The Pin1 WW domain was expressed in E. coli (BL21(DE3)) using M9 minimal media 
containing 15N-NH4Cl (Cambridge Isotope Laboratories, Inc.). Cells were induced at OD600 of 
0.6 ~ 0.8 by adding 1mM final concentration of Isopropyl β-D-1-thiogalactopyranoside (IPTG) 
at 37°C and harvested at OD600 of 2.0. The Pin1 gene was inserted into a pET28 vector with 
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Kanamycin resistance as a fusion protein with an N-terminal His6-tag. Pin1 was expressed in LB 
culture. The cells were induced at OD600 of 0.6~0.8 by adding 1mM of a final concentration of 
IPTG at 16°C for 20 hours. Synthetic peptides pSer110 (comprised of IRAKM residues 103-124 
with Ser110 phosphorylated, TNYGAVL(pS)PSEKSYQEGGFPNI), and IRAKM Ser110E 
(IRAKM residues 103-124 with the Ser110E substitution), were purchased from Tufts 
University, Core Facility, Boston, MA.  
Nuclear magnetic resonance (NMR) experiments were performed on a Varian Inova 
600-MHz spectrometer at 25 °C. NMR spectra were processed and analyzed using NMRPipe 
and Sparky software (7, 8). The composite chemical shift change in the 2D 1H -15N HSQC was 
monitored during NMR titration experiments and was fit to the standard bimolecular binding 
equation as described (equation 1) (6). The Solver function in Excel (Microsoft) was used to fit 
the data to the standard bimolecular binding equation (Equation 1):   
2
]][[4)][]([][][
]:[
2 IRAKMoWWoKIRAKMoWWoKIRAKMoWWo
IRAKMWW DD


  Equation 1
 
In the above equation for a two-state binding equilibrium (free and bound) between protein and 
ligand, KD is the dissociation constant, [WWo] refers to the total concentration of WW domain in 
sample, [IRAKMo] refers to the total concentration of synthetic IRAK-M peptide, and 
[WW:IRAK-M] refers to the concentration of protein:peptide complex.  
To quantify the binding affinity between the Pin1 WW domain and peptides, the 15N 
labeled Pin1 WW domain was titrated with the each of the synthetic peptides, pSer110 and 
IRAKM Ser110E. A reverse titration method was used, where the 15N labeled protein was mixed 
with high concentration synthetic peptide for the first sample. Subsequent samples were a serial 
dilution of this sample with one part derived from the previous sample and one part from a stock 
solution of the 15N labeled Pin1 WW domain at the same concentration as the 15N labeled Pin1 
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WW domain in the first sample. This resulted in a titration where the concentration of the 15N 
Pin1 WW domain was constant, and the concentration of synthetic peptide decreased by a factor 
of ½ in each successive sample. For each of the pSer110 and IRAKM Ser110E peptides, a 1H -
15N HSQC of each titration point was acquired on a Varian Inova 600-MHz spectrometer at 
25 °C, and the resulting composite chemical shift changes, ∆ω, were quantified using Equation 
2: 
∆ω = ට(𝛿ு − 𝛿ு
௙௥௘௘)ଶ + (0.154 × ൫𝛿ே − 𝛿ே
௙௥௘௘൯)ଶ    Equation 2 
 
In Equation 2, 𝛿௜ is the chemical shift of dimension i, and 𝛿௙௥௘௘  is the chemical shift of the 
free state (6).  The composite chemical shift change as a function of titrated ligand was used to 
obtain the concentration of bound complex, [WW:IRAKM], at each titration point using 
Equation 3: 
∆ω = [ௐௐ:ூோ஺௄ெ]×(ఋ
್೚ೠ೙೏ିఋ೑ೝ೐೐)
[ௐௐ೟೚೟]
       Equation 3 
 
The KD value was subsequently fit using Equation 1.  
For the quantification of Pin1 isomerization of peptides pSer110 and IRAKM Ser110E, 
homonuclear 2D rotating-frame overhauser effect spectroscopy (ROESY) NMR experiments 
were performed. For Pin1 catalysis of pSer110, 13.8µM of Pin1 was added to 4.44mM of 
pSer110, and ROESY experiments were acquired with 0ms, 4ms, 8ms, 20ms, 40ms, 60ms, 
80ms, 100ms, and 150ms mixing times. For Pin1 catalysis of IRAKM Ser110E, 20 µM of Pin1 
was added to 4.18mM of IRAKM Ser110E, and ROESY experiments were acquired with 0ms, 
16ms, 20ms, 40ms, 60ms, 80ms, 100ms, and 150ms mixing times. For the appropriate controls, 
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each of pSer110 and IRAKM Ser110E was detected by ROESY without Pin1. The ratios trans to 
cis were measured by Total Correlation Spectroscopy (TOCSY) for both pS110 and IRAKM 
Ser110E. The intensity ratios of cross peaks to diagonal peaks for cis and trans conformation in 
the ROESY spectra were fit using the equations 4 (9) 
 
𝐼௖௖(𝑡௠) =
𝐼௖(0){−(𝜆ଶ − 𝑎ଵଵ)𝑒ିఒభ௧೘ + (𝜆ଵ − 𝑎ଵଵ)𝑒ିఒమ௧೘ }
𝜆ଵ − 𝜆ଶ
 
𝐼௧௧(𝑡௠) =
𝐼௧(0){−(𝜆ଶ − 𝑎ଶଶ)𝑒ିఒభ௧೘ + (𝜆ଵ − 𝑎ଶଶ)𝑒ିఒమ௧೘}
𝜆ଵ − 𝜆ଶ
 
𝐼௖௧(𝑡௠) =
ூ೎(଴){௔మభ௘షഊభ೟೘ି௔మభ௘షഊమ೟೘ }
ఒభିఒమ
  Equations 4 
𝐼௧௖(𝑡௠) =
𝐼௧(0){𝑎ଵଶ𝑒ିఒభ௧೘ − 𝑎ଵଶ𝑒ିఒమ௧೘ }
𝜆ଵ − 𝜆ଶ
 
𝜆ଵ,ଶ = 1/2{(𝑎ଵଵ + 𝑎ଶଶ) ± ට(𝑎ଵଵ − 𝑎ଶଶ)ଶ + 4𝑘௖௧௖௔௧𝑘௧௖௖௔௧  } 
𝑎ଵଵ = 𝑘௖௧௖௔௧ + 𝑅ଶ,௖ , 𝑎ଶଶ = 𝑘௧௖௖௔௧ + 𝑅ଶ,௧, 𝑎ଵଶ = −𝑘௧௖௖௔௧ , 𝑎ଶଵ = −𝑘௖௧௖௔௧  
 
In the above equations, R2,c and R2,t are the transverse relaxation rates of magnetization in cis and 
trans isomer states, kctcat and ktccat represent the exchange rates between cis and trans, and Ic(0) 
and It(0) are the transverse magnetization of the cis and trans isomer states at the beginning of 
the mixing time tm. R2, transverse relaxation rates, were measure by fitting to a single 
exponential equation, I(t)=I(0)Exp(-t*R2), where I is an intensity of trans/cis peaks (9). We fit 
the data to equations 4 rather than the simplified equation that assumes trans and cis populations 
are equal, because the populations of cis and trans are significantly different in both pSer110 and 
IRAKM Ser110E peptides.  
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Results 
Pin1 directly interacts with phospho-Ser110 and Ser110E IRAKM peptides in vitro 
To determine whether Pin1 can directly interact with the phosphorylated serine 110 
(pSer110) site in IRAKM and with the Ser110E mutant of this motif, two-dimensional nuclear 
magnetic resonance spectroscopy (NMR) was employed. For detection of binding, the WW 
domain of Pin1, which facilitates binding to Pin1 substrates, was uniformly labeled with 15N, 
providing the ability to use NMR to detect residue-specific changes in the chemical environment 
that result from the addition of unlabeled IRAKM peptide. The covalently bonded nitrogen and 
amide proton (NH) of each residue in the 15N-labeled Pin1 WW domain yields a peak in the two-
dimensional 1H-15N Heteronuclear Single Quantum Coherence (HSQC) spectrum (Figure 2.1 a). 
The coordinates of each peak, given by the chemical shift in each of the nitrogen and proton 
dimensions, are sensitive to the chemical environment of the NH group and thereby serve as 
sensors to detect ligand binding. The kinetics of ligand binding can be in either fast or slow 
exchange, inducing peaks to move with increasing ligand concentration or causing the 
appearance of new peaks, respectively. The induced chemical shift perturbation (∆δ) of the 15N-
labeled Pin1 WW domain observed during titration with the IRAKM peptides can be 
quantitatively analyzed to yield binding affinity (6). 
 The binding of the 15N-labeled Pin1 WW domain to the phosphorylated IRAKM 
(pSer110) and IRAKM Ser110E peptides was monitored using the 1H-15N HSQC experiment. 
For titrations using each peptide, the positions of several peaks in the spectrum of 15N Pin1 WW 
domain change with increasing peptide concentration, moving toward their respective positions 
in the spectrum of the saturated complex (Figure 2.1 b-e). This peak movement with the addition 
of ligand demonstrated fast exchange kinetics and allowed the corresponding dissociation 
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constant (KD) for each peptide to be determined from the induced chemical shift perturbation as 
described in Materials and Methods (6).  The composite chemical shift titration curves were 
well fit using the simple two-state binding model (Figure 2.2).  The resulting dissociation 
constant (KD) between the Pin1 WW domain and pSer110 was 60.7µM±11.5µM (mean ± s.d.), 
and KD between the Pin1 WW domain with IRAKM Ser110E was 1.51mM ± 0.22mM (mean ± 
s.d.).   
Isomerization by Pin1 
Pin1, which consists of both a WW domain and a Peptidyl-prolyl-cis-trans-isomerase 
domain (PPIase), accelerates the isomerization of specific phosphorylated S/T-P motifs.  In 
cellular experiments performed by the Lu lab, Pin1-K63A, a catalysis deficient Pin1 mutant 
could not stabilize IRAKM, which suggests that isomerization may be necessary for IRAKM 
stabilization (5). Moreover, the IRAK-M(S110E) mutant showed enhanced Pin1-dependent 
stabilization, suggesting that Pin1 might also catalyze the E-P peptide bond in IRAK-M(S110E). 
To determine whether Pin1 catalyzes isomerization of the pIRAKM and IRAKM Ser110E 
peptides, homonuclear 2D rotating-frame overhauser effect spectroscopy (ROESY) NMR 
experiments were performed. The intensities of exchange cross peaks and diagonal peaks for the 
two isomer states, cis and trans, are changed depending on the exchange rates (ktc, kct), and on 
the ROESY mixing time (tm).  
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Figure 2.1.  IRAKM-pSer110 binds to Pin1. (a) The full 1H-15N HSQC spectrum of WW 
domain titration with the IRAKM-pSer110 peptide with apo labeling. (b-e) Chemical shift 
perturbations in extracted regions of the 1H-15N HSQC spectrum of 15N-labeled Pin1 WW 
domain resulting from titration with the IRAKM-pSer110 peptide. Overlaid spectra of apo (5) 
a 
d 
c b 
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and increasing amounts of ligand (rainbow of colors, with purple as highest ligand 
concentration).   
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Figure 2.2. Plot of composite chemical shift change () (Equation 2) (6) as a function of a) 
pIRAKM concentration or b) IRAK-M S110E concentration for a selection of 15N-WW domain 
residues.  Filled circles represent experimental values, and solid lines denote best-fit two-state 
binding model curves for the indicated residues 
 
When Pin1 is present, exchange cross-peaks between cis and trans isomers appeared in 
ROESY spectra of both pIRAKM (phosphorylated Ser-Pro) and IRAKM Ser110E (Glu-Pro) 
peptides (Figure 2.3).  Conversely, in the absence of Pin1, exchange cross-peaks between cis 
and trans isomers of the peptide bond were missing for both pIRAKM and IRAKM Ser110E 
peptides (Figure 2.3). These results show that Pin1 catalyzes the cis-trans isomerization of 
phosphorylated Ser-Pro motif, and phosphomimetic mutation Glu-Pro as well. These results 
support a direct Pin1 interaction with pIRAK-M and IRAK-M Ser110E, and provide insights into 
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possible mechanisms by which Pin1 might affect IRAKM stabilization in-vivo.   
 
 
Figure 2.3.  Homonuclear two-dimensional 1H-1H rotating frame Overhauser effect correlation 
spectroscopy spectra of phosphorylated IRAKM peptide or IRAKM S110E peptide in the 
presence of Pin1 or absence of Pin1. Diagonal (labeled cc or tt) and cross peaks (labeled ct and 
tc) for the amide proton of Ser110 (or E110) are connected by dashed lines. In the presence of 
Pin1, cross peaks between cis and trans appear for both phosphorylated IRAKM peptide and 
IRAKM-S110E peptide. In the absence of Pin1, no cross peaks were observed. 
 
Acquisition of ROESY spectra at a series of mixing times allowed quantification of the 
Pin1-catalyzed isomerization rate for both pIRAK-M and IRAK-M Ser110E peptides, as 
described in Materials and Methods. The intensities of the diagonal peaks decreased and 
exchange peaks increased with increasing tm (10) (Figure 2.4).  Fitting of these curves to 
Equations 4 (above) yielded isomerization rates of 28.98 s-1 for pSer110 and 0.84 s-1 for 
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Ser110E(Table 2.1).  
 
Figure 2.4. The intensities of exchange and diagonal peaks in ROESY spectra for pSer110 and 
IRAKM Ser110E depend on the ROESY experiment mixing time (tm).  
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Table 2.1. Isomerization rates of pSer110 and IRAKM Ser110E by Pin1 
 pSer110 Ser110E 
Concentration 4.4 mM 4.18mM 
Pin1 13.8 µM 20 µM 
trans/cis 10.7 6.87 
R2 (s-1) <Trans, Cis> 6.8, 7.5 7.2, 8.6 
kex (s-1) 28.98 0.84 
ktc (s-1) 2.48 0.11 
kct (s-1) 26.50 0.73 
 
 
Discussion 
These NMR results indicate that Pin1 not only binds to but also catalyzes cis/trans 
isomerization of the pS110-Pro motif in IRAKM. Of additional great interest are the findings 
that Pin1 interacts with IRAKM Ser110E, the analogous phosphomimetic synthetic peptide, and 
catalyzes cis/trans isomerization of the Glu-Pro peptide bond in this peptide . The dissociation 
constant KD between Pin1 and phosphorylated IRAKM peptide is a smaller value (stronger 
affinity) than KD between Pin1 and IRAKM S110E peptide, but Pin1 still interacts with the Glu-
Pro site. In addition, the isomerization rate of the pS110-Pro motif is faster than the 
isomerization of the Glu-Pro by Pin1. However, the isomerization rate of Glu-Pro by Pin1 is 
much faster than without Pin1.  Previous studies regarding the specificity of Pin1 for 
phosphoSer/Thr-Pro versus Glu-Pro showed that Glu-Pro is around 10- to 20-fold weaker that 
phosphoSer/Thr-Pro in Pin1 PPIase assays, but that this level of activity is sufficient to be used 
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as a substrate for Pin1 PPIase assays (11-13). These results suggest that the IRAKM S110E 
mutant might function as a constitutive Pin1 substrate in cells. 
To pursue the hypothesis that IRAKM S110E might serve as a constitutively active Pin1 
substrate in cells and function similar to IRAKM phosphorylated at S110, our collaborators 
stably expressed either wild type IRAKM or IRAKM S110E in the DC2.4 mouse dendritic cell 
line (5).  The Glu mutation mimics phosphorylation by placement of a negative charge, but is in 
a “permanent” negatively charged state, rather than a reversible one. Because stimulation of 
DC2.4 cells with IL-33 induces IRAKM phosphorylation at S110 and activation of Pin1, the 
effects of IL-33 treatment on wild type and S110E IRAKM stability and subcellular localization 
were compared.  While the Pin1-IRAKM interaction was evident only after IL-33 stimulation, 
for IRAK-M S110E a much weaker PIN1 interaction was evident even before IL-33 stimulation. 
Interestingly, S110E IRAKM showed higher nuclear localization that wild type IRAKM, 
indicating that IRAK-M nuclear localization seems to be dependent on S110 phosphorylation 
and on PIN1.  Finally, while wild type IRAKM is rapidly degraded via the proteasome, the 
phosphomimetic mutation S110E rendered IRAK-M completely resistant to degradation in 
mouse embryonic fibroblasts (MEFs), indicating that the permanent negative state of IRAKM 
evades proteasomal degradation. These results suggest that pSP IRAKM is protective against 
degradation, while SP IRAKM is susceptible to degradation. Moreover, the dependence of this 
protection on Pin1 implies that the interaction of pSP IRAKM or EP IRAKM with Pin1 protects 
IRAKM from proteasomal degradation, while SP IRAKM that is unable to interact with Pin1 is 
degraded.  Overall, these cell biology experiments support the hypothesis that IRAKM S110E 
serves as a constitutive Pin1 substrate in mouse cells. 
Our NMR results demonstrate that Pin1 binds to and catalyzes cis/trans isomerization of 
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the pS110-Pro motif and its E110-Pro phosphomimetic mutant in IRAKM. These results suggest 
that Pin1 interacts with pSP IRAKM directly in vivo as well, and that this interaction might play 
a central role in innate immunity.  Indeed, through collaboration we have shown that IRAK-M 
has a distinctive function upon IL-33 stimulation where it serves as a significant mediator for IL-
33 signaling in DCs in a manner dependent on IRAKM phosphorylation at S110 and on Pin1 (5).  
These synergistic NMR and biological studies have shown that the IL-33-PIN1-IRAK-M is an 
axis critical for dendritic cell activation, type 2 immunity and IL-33 induced airway 
inflammation, and offer new therapeutic targets for allergic asthma (5). 
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Chapter 3 
 
1H, 13C, 15N backbone and sidechain resonance assignments of human R56D, 
Y61E variant of the IRAK-M death domain 
 
Abstract 
Innate immunity provides the first line of defense against bacterial and viral pathogens. Toll-like 
receptors (TLRs) act as sentinels to detect specific pathogen-associated molecular patterns. TLR 
stimulation launches signaling cascades that induce type I interferons (IFNs), inhibitory factors 
and pro-inflammatory cytokines, thereby initiating and regulating innate and adaptive immunity. 
Loss of proper innate immunity regulation leads to inflammation-related diseases such as 
asthma. IRAK-M is a known negative regulator of TLR/IL-1R signaling, and is thought to 
assemble into activated TLR/IL-1R signaling complexes to regulate downstream signaling. The 
IRAK-M N-terminal death domain (IRAK-M DD) mediates interactions with components of 
these signaling complexes, yet the specific interaction interfaces have not been experimentally 
determined. The wild type IRAK-M DD has eluded structure determination due to aggregation of 
the recombinantly expressed domain. Here, we report the 1H, 13C and 15N backbone and 
sidechain resonance assignments for a soluble monomeric double-mutant IRAK-M DD (R56D, 
Y61E) that is well suited for NMR studies.  These NMR resonance assignments will enable 
structural and dynamics studies to investigate the detailed mechanisms by which the IRAK-M 
DD associates with activated TLR/IL-1R signaling complexes to regulate innate immunity 
signaling. 
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Biological context  
 
Allergic asthma is the most frequently occurring type of asthma, and is triggered by 
TLR-mediated detection of signals from extracellular pathogens [1].  TLRs positioned at the 
surface of epithelial cells and dendritic cells (DCs) detect airborne allergens such as 
microorganisms, house dust mites, and viral proteins, and upregulate innate immunity signaling 
cascades through the expression of cytokines that induce inflammation [2, 3]. When production 
of cytokines is not properly regulated, the resulting inflammation causes contraction of muscles 
around the airways [4]. TLRs initiate signaling cascades through MyD88 and IL-1R-associated 
kinase (IRAK) family members that trigger inflammation via NF-κB signaling [5]. There are 
four members of the IRAK family, namely IRAK1, IRAK2, IRAK-M and IRAK4 [6, 7]. 
TLR activation leads to receptor dimerization and possibly to higher order receptor 
clustering, and to the subsequent assembly of a multi-protein signaling complex known as the 
Myddosome [8]. The x-ray crystal structure of the Myddosome suggests that this signaling 
complex anchors to the cytoplasmic TIR domains of activated receptors via four MyD88 
subunits, and extends into the cytosol through assembly of four IRAK4 subunits onto the MyD88 
tetramer, followed by assembly of four IRAK1 or IRAK2 (IRAK1/2) subunits onto the IRAK4 
tetramer [9].  The MyD88, IRAK4 and IRAK1/2 homotetramer layers are formed by the death 
domain of each subunit, generating a hetero-oligomeric death domain scaffold terminated by a 
tetramer of IRAK1 or IRAK2 death domains [9].  
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IRAK family members consist of an N-terminal death domain (DD), a linker, a Ser/Thr 
kinase domain (KD), and an intrinsically disordered C-terminal domain. Associations between 
different IRAK family members are mediated by intermolecular interactions between their 
respective DDs [9].  The IRAK family member IRAK-M is a known negative regulator of Toll-
like receptor signaling and is essential for normal function of the innate immune system [10]. 
IRAK-M also is a positive mediator of IL-33 induced inflammation [11].  Consequently, IRAK-
M has important implications for asthma.  While the IRAK-M DD is implicated in these 
functions, the detailed mechanisms of these effects are not yet elucidated. It has been proposed 
that IRAK-M is recruited via its DD to the Myddosome complex to directly block downstream 
signaling [9]. Alternatively, it has been recently found that IRAK-M induces inhibitory 
molecules through TLR7 as part of a second wave of signaling in response to endocytosed 
pathogen [12]. Even though the role of IRAK-M and its DD in Toll-like receptor signaling is 
well established, the structural mechanisms by which IRAK-M DD regulates TLR signaling are 
only beginning to be illuminated.  
In pursuit of the NMR structure of the IRAK-M DD, we found that the recombinantly 
expressed domain is not soluble and rapidly aggregates. Based on the hypothesis that aggregation 
was due to higher order oligomerization, we designed mutations to impart electrostatic repulsion 
between predicted subunit interfaces, yielding a double mutant (R56D, Y61E) with high 
solubility as a monomer.  As a first step toward structure-function studies of this domain, we 
present here the backbone and sidechain chemical shift assignments of a 124-residue protein 
construct in which residues 1-5 represent non-native amino acids resulting from insertion cloning 
(italicized in Figure 3.1A), and residues 6-124 correspond to native IRAK-M residues 1-119 with 
mutations R56D and Y61E (Figure 3.1A).  
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Methods and experiments 
Protein expression and purification 
The human IRAK-M (IRAK3, NCBI: NM_007199.2)[1-119] gene was inserted into the 
pMAL-c2X vector with maltose binding protein (MBP) as an N-terminal fusion partner, 
separated by a Factor XA cleavage site. A vector harboring the R56D and Y61D mutations was 
made from this vector using a single primer (forward primer, with mutations underlined: 5’ AGC 
AGC TGG CTG GAT GTT GAT CAT ATT GAA AAG GAT GTA GAC CAA GGT AAA 
AGT G 3’) and the BIO RAD-iProof High-Fidelity DNA Polymerase.  The resulting expression 
plasmid, pMAL-c2X, encodes the MBP-IRAK-M[1-119:R56D,Y61D] fusion protein, with a 
Factor XA cut site between MBP and IRAK-M[1-119:R56D,Y61D]. Further mutagenesis of this 
vector to change Y61D to Y61E was similarly achieved using a single primer (forward primer, 
D61E, with mutation underlined: 5’ GTT GAT CAT ATT GAA AAG GAG GTA GAC CAA 
GGT AAA AGT GG 3’) and the BIO RAD-iProof High-Fidelity DNA Polymerase to generate 
expression plasmid pMAL-c2X encoding the MBP-IRAK-M[1-119:R56D,Y61E] fusion protein 
with a Factor XA cut site between MBP and IRAK-M[1-119:R56D,Y61E]. The MBP-IRAK-
M[1-119:R56D,Y61E] vector with Ampicillin resistance was transformed into BL21-Gold(DE3) 
cells (Agilent Technologies) and screened by Carbenicillin LB-agar plate. A single colony was 
inoculated to 10ml LB (Luria broth) culture and incubated at 37°C for 8 hours. Cells were 
collected by gentle centrifugation at 2000g, cells were transferred to 100ml of M9 minimal 
media with 1g/L of 15NH4Cl as the sole nitrogen source and 4g/L of 13C glucose as a sole carbon 
source, and incubated at 37°C for 16 hours. The dense cells were transferred to two flasks each 
containing 1L M9 minimal media (same as 100ml starter culture), and were induced at 0.8 OD600 
by adding 1mM of final concentration of IPTG at 37°C for 6 hours.   
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Cells were harvested by centrifugation at 3500g. The cell pellet was dissolved in 40ml of 
wash buffer (20mM Tris, 200mM NaCl, 1mM EDTA, and 0.2mM TCEP, pH 7.4) with 40mg of 
lysozyme (Amresco) and 100µl of PI cocktail (Thermo Fisher Scientific, EDTA-free), and 
incubated 30min on ice. The dissolved cells were sonicated on ice, alternating 1 second 
sonication and 1 second pause for 1min, for four 1min cycles. Cell debris was removed by 
centrifugation, the supernatant was incubated with 5 mL of Amylose Resin (New England 
BioLabs), pre-equilibrated with wash buffer, for 5hours at 4°C. The column was washed with 4 
bed volumes of wash buffer, and the fusion protein was eluted with 2 bed volumes of elution 
buffer (10mM of Maltose added to wash buffer). Eluted fusion protein was dialyzed into Factor 
Xa cleavage buffer (20 mM Tris-HCl, 100 mM NaCl, 2 mM CaCl2, pH = 8.0).  Factor Xa 
Protease (New England BioLabs) was added (100ul of 1ug/ul to 20ml of fusion protein) and the 
solution was gently rocked at room temperature for overnight. The cleaved proteins were 
concentrated to 2ml and loaded onto a size exclusion FPLC column (GE SuperdexTM 75 prep 
grade), and run with FPLC buffer (10mM Tris, 20mM NaCl, and 0.2mM TCEP, pH 8.0). Eluted 
fractions of IRAKM[1-119:R56D,Y61E] were collected, pooled and concentrated. The pH was 
adjusted to 6.7 using 0.1M HCl, and total concentration of 5mM of TCEP and 5mM of NaN3 
was added. IRAK-M[1-119:R56D,Y61E] concentration was measured by UV absorption at 280 
nm (extinction coefficient = 25105 cm-1 M-1), and final concentration was 800µM in 300µL. 
 
NMR spectroscopy 
All NMR spectra were recorded at 25°C on a Varian Inova 600MHz spectrometer 
equipped with a 1H/13C/15N triple resonance probe with Z-axis gradient. A uniformly 15N-labeled 
IRAK-M[1-119:R56D,Y61E] sample was used to collect 2D 15N-1H HSQC spectra and 3D 1H-
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15N NOESY and 1H-15N TOCSY spectra. A uniformly 13C/15N-labeled sample was used to 
collect 2D 1H-15N HSQC spectra and 3D HNCA, HN(CO)CA, HNCO, HN(CA)CO, CBCANH, 
CBCA(CO)NH, H(CCO)NH, C(CO)NH, HCCH-TOCSY, 1H-13C aliphatic NOESY, and 1H-13C 
aromatic NOESY spectra.  Backbone assignments were obtained from 1H-15N HSQC, 1H-15N 
NOESY, 1H-15N TOCSY, HNCA, HN(CO)CA, HNCO, HN(CA)CO, CBCANH, 
CBCA(CO)NH, H(CCO)NH, C(CO)NH, and HCCH-TOCSY spectra. Aromatic ring resonances 
were assigned using the 2D 1H-15N NOESY, 3D 1H-13C aliphatic NOESY, and 3D 1H-13C 
aromatic NOESY spectra. Carbonyl resonances were assigned using a HNCO spectrum. 
Assignments were determined using PINE [13] imbedded in NMRFAM-SPARKY [14-16], 
followed by human adjustments. 
 
Assignments and secondary structure 
 Backbone assignments are complete except for S55, numbered according to protein 
construct (Figure 3.1A, red numbering).  The assigned 15N-1H-HSQC spectrum (Figure 3.1B) 
also uses the numbering scheme of the full construct. Backbone assignments are 97% complete, 
and sidechain assignments 85% complete. 87% of overall assignments are complete. These 
backbone and sidechain chemical shift assignments have been deposited in the BioMagResBank 
(http://www.bmrb.wisc.edu/) with accession number 30237.  PECAN embedded in PINE 
provided secondary structure predictions based on the NMR chemical shift assignments for the 
IRAK-M DD sequence [17]. IRAK-M[1-119:R56D,Y61E] is predicted to consist of 6 α-helices 
and connecting loops (Figure 3.2), in good agreement with other known death domain structures 
such as IRAK2 DD and IRAK4 DD [9].  In future work these chemical shift assignments will 
be used to study the mechanisms by which IRAK-M carries out its varied regulatory roles in 
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innate immunity signaling. 
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Figure 3.1 a. Primary sequence of IRAKM[1-119:R56D,Y61E], with numbering corresponding 
to native IRAK-M (black) and protein construct numbering (red). b. 1H-15N HSQC spectrum of 
13C/15N-IRAKM[1-119:R56D,Y61E], with peak assignments labeled according to protein 
construct numbering (consistent with numbering of BioMagResBank accession number 30237). 
The inset shows the tryptophan indole region of the spectrum. 
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Figure 3.2  Secondary structure prediction for IRAK-M[1-119:R56D,Y61E] by PECAN [17] in 
PINE [13], based on chemical shift and amino acid sequence for predicting low energy 
conformation. Positive probability indicates α-helix and negative probability indicates β-strand. 
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Chapter Four 
 
IRAKM death domain structure determination and insights from simulations 
of docking to the Myddosome 
 
Abstract 
Asthma is a chronic inflammatory sickness of the airways caused by environmental and 
genetic factors. The mechanisms of activation of innate immunity signaling pathways that cause 
asthma are not fully understood yet. This study investigated novel targets for the development of 
new asthma therapeutics, with a specific focus on IRAKM that is a negative regulator within the 
context of Toll-Like Receptor (TLR) signaling. Toll-Like Receptors recognize specific 
molecular markers that are present in microbial components, and transfer these signals through 
their intracellular TIR domains to MyD88 and IRAK family members that assemble into an 
activated signaling complex inside the cell. Assembly of IRAK-M into the TLR signaling 
complex is mediated by its N-terminal death domain (DD). Oligomerization is a hallmark of 
DDs.  The wild-type IRAKM-DD has eluded structure determination due to aggregation. Here, 
we solved the solution NMR structure of a double-mutant IRAKM-DD (R56D, Y61E) that is a 
highly soluble monomer well suited for NMR studies. This experimentally determined structure 
was used in simulations to investigate possible docking of IRAK-M DD into the activated TLR 
signaling complex as well as with multiple IRAK family members and oligomers.  Based on 
these docking studies, a mechanistic model is proposed for IRAKM regulation of IRAK1-
mediated TLR signaling.  
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Introduction 
Innate immunity is an essential first line of defense against invasion by pathogens [1].  
This rapid, built-in immune response is initiated by stimulation of Toll-like receptors (TLRs), a 
family of inherited transmembrane proteins that act as sentinels to detect the presence of viral, 
bacterial and fungal pathogens [2]. TLRs recognize molecular signals distinct to pathogens, such 
as flagellin, double-stranded RNA, and lipopolysaccharides [3-5]. TLR stimulation launches 
signaling cascades that induce type I interferons (IFNs), inhibitory factors and pro-inflammatory 
cytokines, thereby initiating and regulating innate and adaptive immunity (REFS). Pro-
inflammatory cytokines include interleukin-1β (IL-1β), IL-18 and IL-33, whose cognate 
receptors are members of the interleukin-1 receptor (IL-1R) family [6].  Stimulation of IL-1Rs 
further amplifies the immune response and induces inflammation, highlighting the need for tight 
regulation of not only IL-1R signaling, but also of the initiating TLR signaling pathways [7].   
The TLR and IL-1R families are part of the IL-1R/TLR superfamily, classified on the 
basis of possession of a Toll/IL-1 receptor (TIR) domain responsible for their downstream 
intracellular signaling [6, 8].  Intracellular signaling by TLRs (except TLR3) and by the specific 
IL-1Rs stimulated by IL-1β, IL-18 or IL-33 involves a shared set of proteins that are recruited to 
the TIR domains of the activated receptors to form a multiprotein signaling complex known as 
the Myddosome (Figure 4.1) [9]. These shared components include the adaptor protein MyD88, 
which based on possession of its own TIR domain is classified in the IL-1R/TLR superfamily [6, 
9].  MyD88 also possesses a death domain (DD), which is a modular α–helical oligomerization 
domain essential for formation of activated signaling complexes that mediate downstream 
signaling [10-12].   Shared components of this class of intracellular signaling also include the 
interleukin-1-receptor associated kinase (IRAK) family of proteins, which in the vertebrate 
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genome include 4 members: IRAK1, IRAK2, IRAK-M, and IRAK4 [4-8, 13]. IRAK family 
members are important mediators of the TLR/IL-1R signaling pathways.  Each IRAK family 
member contains two folded domains (a death domain and a serine/threonine kinase domain) 
separated by a linker region unique to each member, and a C-terminal region. The kinase 
domains of all but IRAKM (whose kinase domain is inactive) participate in phosphorylation-
mediated signaling events [14-18].  
 
Figure 4.1. Crystal structure of Myddosome complex with aligned IRAKM DD 
MyD88 DD 
IRAK4 DD 
IRAK2 DD 
IRAKM DD 
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IRAK-M is a known negative regulator of Toll-like receptor signaling [9, 10]. Expressed 
in lung epithelial cells [13] and in monocytes and macrophages [11], IRAK-M represses TLR 
signaling in three ways (Figure 4.2). First, IRAK-M associates with IRAK1 to prevent IRAK1 
dissociation from Mydossome complexes and to prevent the formation of downstream IRAK1-
TRAF6 signaling complexes [1, 5]. In support of this negative regulatory model, Kobayashi 
(2002) showed that IRAK1-TRAF6 complex formation was inhibited by IRAK-M expression in 
the 293T cell model [4]. Second, it has been recently found that IRAK-M induces inhibitory 
molecules through TLR7 as part of a MEKK3-mediated second wave of signaling in response to 
endocytosed pathogen [12]. Previous modeling studies have proposed that IRAK-M interacts 
with MyD88-IRAK4 to mediate the MEKK3 dependent pathway, where IRAK-M serves as an 
intermediate signaling component to transmit signaling upon TLR activation [12]. These 
modeling studies also suggested that IRAK-M specifically interacts with IRAK-2, but not with 
IRAK-1, and suppresses IRAK-2 mediated translation of cytokines and chemokines [12].   
Third, IRAK-M has been shown to inhibit the IRAK2-mediated TLR signaling pathway that 
stabilizes specific mRNAs to promote cytokine and chemokine production [3].  Hence, by 
either blocking or promoting signaling, IRAK-M plays key roles in negative regulation of TLR 
signaling. 
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Figure 4.2. Literature-based model for the regulatory role of IRAK-M in TLR signaling (adapted 
from Figure.8 on, Hao Zhou et al, EMBO, (2013)).  Double blue lines represent the plasma 
membrane, black arrows indicate promotion of or flow to the indicated state or consequence, and 
red lines terminated with a “T” indicate inhibition of the indicated step or process.  Encircled 
“P” indicates phosphorylated site(s).  Standard UniProt abbreviations are used for all proteins.  
“X/Y” denotes intermediate involved molecules. 
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Although its major function appears to be repressive, activation of NF-kB by IRAK-M 
when both IRAK1 and IRAK2 were eliminated has also been reported [14, 15]. Overexpression 
of IRAK-M in HEK293 cells activates NF-kB, and this effect is dependent on the IRAK-M N-
terminal DD [31].  In support of specific activation roles of IRAK-M, through collaboration we 
have identified IRAK-M as a novel Pin1 target critical for IL-33 signaling in type 2 (TH2) 
allergic response associated with asthma. Briefly, Pin1 is activated in IL-33-induced airway 
inflammation. Notably, IRAK-M is phosphorylated at its S115-P site by IRAK1 upon IL-33 
treatment, which induces asthma, and phosphorylated IRAK-M is immune-precipitated by Pin1 
antibody [15]. Pin1 binding and isomerization of the pS115-P motif increases IRAK-M nuclear 
translocation and protein stability that correlates with increased expression of a set of pro-
inflammatroy cytokines that induce inflammation. In addition, treatment of mouse models with 
ATRA (a Pin1 inhibitor) or genetic ablation of Pin1 or IRAK-M reduce TH2 polarization, 
dendritic cell (DC) activation and overall lung inflammation upon IL-33 challenge. These results 
were correlated with molecular features of asthma in humans by analyzing samples obtained 
from asthmatic patients challenged with Derp1 (a major allergen of house dust mites), where 
Pin1 activation and IRAK-M levels were increased, and expression of the IRAK-M downstream 
pro-inflammatroy cytokines were increased [15].  
The death domains of IRAK family members are central players in mediating signaling 
and regulatory interactions, which is exemplefied by the Myddosome structure [9]. These 
domains are rich in hydrophobic amino acid side chains such as leucine, isoleucine, and 
tryptophan, and in charged amino acid residues such as negatively charged aspartic acid and 
glutamic acid, and positively charged arginine (Chapter one. Figure 1.4). The DDs of IRAK 
family members have 30 to 39% pairwise similarity (Chapter one. Figure 1.5). The crystal 
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structure of the Myddosome complex, composed of six MyD88 DD, four IRAK4 DD, and four 
IRAK2 DD assembled into a left-handed helical oligomer (Figure 4.1), revealed packing 
interactions involved in hetero- and homo-subunit interactions [8]. Notably, although the DDs of 
MyD88, IRAK4, and IRAK2 have highly similar structures in this complex, the variation in DD 
surface residues between the different proteins enables the sequential and specific assembly of 
the complex.  Importantly, the structure of the IRAK-M DD had not yet been reported.  
In this study, we investigated the structure and interactions of the IRAK-M DD by NMR 
spectroscopy and docking simulations, respectively.  Since we found that the wild-type 
IRAKM-DD is of very limited solubility, mutagenesis was applied to identify a double mutant 
(R56E,Y61D) that adopts the same fold as wild type, is highly soluble, and is highly amenable to 
solution NMR analysis. The high-resolution NMR structure of IRAKM-DD(R56E,Y61D) was 
determined, confirming the expected DD fold and providing important information regarding 
surface-exposed residues.  This structure was used to construct a model of wild type IRAK-M 
DD that was then used to simulate interactions of this domain with the DDs of other IRAK 
family members, individually and in the context of the Myddosome structure. The elucidated 
IRAKM-DD structure, together with the docking results, suggest a mechanism by which IRAM-
M could negatively regulate IRAK1-mediated pro-inflammatory signaling, and by which Pin1 
could regulate this process.  
 
 
 
 
 
 
52 
 
Materials and Methods 
Plasmid Construction 
To construct the expression vector for IRAKM-DD, the pMAL-c2X parent vector with 
Ampicillin resistance was used.  The pMAL-c2X vector contains the tac promoter and lacI, 
enabling protein expression level to be controlled by IPTG concentration. This vector codes for 
the Maltose Binding Protein (MBP), and allows for insertion of a desired gene that will be 
expressed as a fusion partner C-terminal to MBP. The restriction site NdeI is 5’ to the MBP 
gene.  Restriction sites SacI, EcoRI, BamHI, XbaI, SalI, OstI and HindII are located 3’ to the 
MBP gene. Plasmids used are described in detail in Appendix 1. 
 The IRAKM DD gene was PCR-amplified from clone hIRAKM (IRAK3, NCBI: 
NM_007199.2) using the forward primer with BamHI, 5’ act gat gga tcc atg gcg ggg aac tgt ggg 
gcc cgc ggc gcg 3’, and the backward primer with HindIII, 5’ gac agt aag ctt tca acc ttc ctg ata 
act ctt ctc tga agg 3’. The BamHI and HindIII restriction sites were used to cut the PCR insert 
and pMAL-c2X plasmid, and the resulting PCR product and vector pMAL-c2X were ligated 
using sticky ends to yield the pMAL-c2X_IRAKM[1-119] plasmid that expresses MBP fused to 
IRAKM residues 1–119.  
The R56D and Y61D mutations in IRAKM were achieved using the pMAL-
c2X_IRAKM[1-119] vector. PCR amplification and mutagenesis were performed using BIO 
RAD-iProof High-Fidelity DNA Polymerase with forward primer 5’ agc agc tgg ctg gat gtt gat 
cat att gaa aag gat gta gac caa ggt aaa agt g 3’and backward primer 5’ c act ttt acc ttg gtc tac atc 
ctt ttc aat atg atc aac atc cag cca gct gct 3’ to generate the expression plasmid pMAL-c2X 
_IRAKM[1-119:R56D,Y61D]. 
The R56D and Y61E mutations were achieved using the pMAL-c2X-IRAKM[1-
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119:R56D,Y61D] vector, with a single primer (forward primer, D61E, with mutation underlined: 
5’ GTT GAT CAT ATT GAA AAG GAG GTA GAC CAA GGT AAA AGT GG 3’). 
Mutagenesis was performed using BIO-RAD-iProof High-Fidelity DNA Polymerase with 15 
seconds annealing at 65°C and 2 minutes 30 seconds extension at 72°C for 30 cycles. The 
resulting expression plasmid, pMAL-c2X-IRAKM[1-119:R56D,Y61E], encodes the MBP-
IRAKM[1-119:R56D,Y61E] fusion protein, with a Factor XA cut site between MBP and 
IRAKM[1-119:R56D,Y61E]. 
Protein expression and purification 
The pMAL-c2X-IRAKM[1-119:R56D,Y61E] vector with Ampicillin resistance was 
transformed into BL21-Gold(DE3) cells (Agilent Technologies) and screened by Carbenicillin 
LB-agar plate. A single colony was inoculated to 10ml LB (Luria broth) culture and incubated at 
37°C for 8 hours. Cells were collected by centrifugation at 2000g as gentle condition, and cells 
were transferred to 100ml of M9 minimal media with 1g/L of 15NH4Cl as the sole nitrogen 
source and 4g/L of 13C glucose as a sole carbon source and incubated at 37°C for 16 hours. The 
dense cells were transferred to two of 1L M9 minimal media same as a 100ml starter culture and 
were induced at 0.8 OD600 by adding 1mM of a final concentration of IPTG at 37°C for 6 hours.   
Cells were harvested by centrifugation at 3500g. The cell pellet was dissolved in 40ml of 
wash buffer (20mM Tris, 200mM NaCl, 1mM EDTA, and 0.2mM TCEP, pH 7.4) with 40mg of 
lysozyme (amresco) and 100µl of PI cocktail (Thermo,EDTA-free), and incubated 30min on the 
ice. The dissolved cells were sonicated on ice, 1 second sonication and 1 second pause for 1min, 
four cycles. Cell debris was removed by centrifugation, the supernatant was incubated with 5 mL 
of Amylose Resin (BioLabs), pre-equilibrated with wash buffer, for 5hours at 4°C. The column 
was washed with 4 bed volumes of wash buffer, and the fusion protein was eluted with 2 bed 
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volumes of elution buffer (10mM of Maltose added to wash buffer). Eluted fusion protein was 
dialyzed into Factor Xa cleavage buffer (20 mM Tris-HCl, 100 mM NaCl, 2 mM CaCl2, pH = 
8.0).  Factor Xa Protease (NEW ENGLAND BioLabs) was added (100ul of 1ug/ul to 20ml of 
the fusion protein) and the solution was gently rocked at room temperature for overnight. The 
cleaved proteins were concentrated to 2ml and loaded onto a size exclusion FPLC column (GE 
SuperdexTM 75 pg), and run with FPLC buffer (10mM Tris, 20mM NaCl, and 0.2mM TCEP, 
pH 8.0). Eluted fractions of IRAKM[1-119:R56D,Y61E] were collected, pooled and 
concentrated. The pH was adjusted to 6.67 using 0.1M HCl, and the total concentration of 5mM 
of TCEP and 5mM of NaN3 was added. IRAKM[1-119:R56D,Y61E] concentration was 
measured by UV absorption at 280 nm (extinction coefficient = 25105 cm-1 M-1), and final 
concentration was 800µM in 300µL. 
NMR spectroscopy 
All NMR spectra were recorded at 25°C on a Varian Inova 600MHz spectrometer 
equipped with a 1H/13C/15N triple resonance probe with Z-axis gradient. For structure 
determination, two and three dimensional NMR spectra were acquired as described in Chapter 3, 
using the experimental parameters summarized in Table 4.1.  
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Table 4.1. NMR parameters 
 NT(H) Ni(C) Ni(N) SW(H) SW(C) SW(N) OBS(H) OBS(C) OBS(N) CAR(H) CAR(C) CAR(N) 
NHSQC 2048 - 512 8000 - 2000 599.357 - 60.739 4.773 - 118.733 
CHSQC 2048 512 - 8000 21102.69 - 599.357 150.713 - 4.773 70.026 - 
HNCA 2048 128 128 8000 4522 2000 599.357 150.716 60.739 4.773 56.128 118.733 
HNCACO 2048 128 128 8000 3770.1 2000 599.357 150.716 60.739 4.773 174.122 118.733 
HNCO 2048 128 128 8000 3770.1 2000 599.357 150.733 60.739 4.773 174.122 118.733 
HNCOCA 2048 128 128 8000 4522 2000 599.357 150.716 60.739 4.773 56.128 118.733 
CCONH 2048 256 64 8000 12057.14 2000 599.357 150.714 60.739 4.773 46.128 118.733 
CBCACONH 2048 128 128 8000 12058.68 2000 599.357 150.714 60.739 4.773 46.128 118.733 
CBCANH 2048 128 128 8000 12057.14 2000 599.357 150.714 60.739 4.773 46.128 118.733 
HCCHTOCSY 2048 128 256(H) 8000 12059.09 8000(H) 599.357 150.714 599.357(H) 4.773 43.127 4.773(H) 
CNOESY_Aliph 2048 128 256(H) 8000 12059.09 8000(H) 599.357 150.714 599.357(H) 4.773 43.127 4.773(H) 
CNOESY_AROM 2048 128 128(H) 8000 12059.09 8000(H) 599.357 150.714 99.357(H) 4.773 124 4.773(H) 
CCHTOCSY 2048 128 128 8000 12059.09 12058.42 (C) 599.357 150.709 150.709(C) 4.773 35.128 35.128(C) 
SW - Spectral Width (Hz), OBS - Observe Freq (MHz), CAR - Center Position (PPM)
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Solving protein structure by NMR 
The chemical shifts that were determined as described in Chapter 3 (BioMagResBank- 
http://www.bmrb.wisc.edu/, accession number 26941), along with 3D 1H-15N NOESY, 3D 1H-
13C aliphatic NOESY, and 3D 1H-13C aromatic NOESY were used for solving the IRAKM[1-
119:R56D,Y61E]  structure. We submitted the chemical shifts and three sets of raw NOESY 
spectra in ‘.ucsf’ format to Ponderosa Client.  Ponderosa Client is an online tool for submitting 
input to the Ponderosa Server (http://ponderosa.nmrfam.wisc.edu/), an automated NOE 
assignment and structure determination tool. Once Ponderosa Server completes the calculations, 
Ponderosa produces and sends a zip file that contains NOE information with initial structures. 
The files from Ponderosa server were analyzed using Ponderosa Analyzer to validate and refine 
the structure. The Blacklist/Whitelist were built by checking the structure (Pymol) and NOE 
peaks (NMR spectra) and resubmitting the data several times to Ponderosa Client (Figure 4.3). 
Blacklist and Whitelist are graphical weighting factors of inter-residue contacts. Before every 
resubmission of the data for refinement, the limits for distance and angle constraints were 
carefully removed or reset (Figure 4.4). The structure determination process requires the 
following steps for submitting data to Ponderosa Client: 1) Ponderosa refinement, 2) Ponderosa-
X refinement, 3) Constraints only-X, 4-a) Constraints only-X for final step with implicit 
solvation, and 4-b) Constraints only-X for final step with explicit solvation. Ponderosa 
refinement (step 1) uses CYANA automation, and the rest of the steps use XPLOR-NIH [20-23].  
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Figure 4.3. Ponderosa Analyzer  
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Figure 4.4. Ponderosa analyzer validator tools. 
 
Protein docking simulations 
Docking simulations were performed using the protein docking prediction server 
ClusPro (https://cluspro.bu.edu/home.php). ClusPro can simulate protein docking of oligomer 
forms, which was essential for the studies performed here 40-41 [24-27]. ClusPro employs 
PIPER, an FFT-based docking program that uses a pairwise interaction potential as part of its 
scoring function that combined Eatt (attraction), Erep (repulsive), Eelec (electrostatic energy), 
and EDARS (Decoys As the Reference State) [30]. 
  
For docking of IRAK-M DD into a Myddosome containing IRAK1, SwissModel was 
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used to build a homology model of the IRAK-1 DD using IRAK2 DD subunits L, M and N in the 
3MOP structure as templates, and three copies of the resulting homology model were aligned 
with the L, M and N IRAK2 subunits in the Myddosome complex (3MOP) to generate a 
Myddosome model with three IRAK-1 DD subunits and an empty space at the K subunit 
position.  IRAK-M was docked with this modified oligomer (composed of six MyD88, four 
IRAK4 and three IRAK1 DD subunits) using ClusPro. For docking of IRAK-M DD into a 
Myddosome containing IRAK2, the K subunit of IRAK2 was removed from the Myddosome 
structure, and docking of IRAK-M DD to this complex (composed of six MyD88, four IRAK4 
and three IRAK2 DD subunits) was simulated using ClusPro. 
Root mean square deviation (RMSD) calculations. 
The PDB files that were evaluated structural differences were opened in SwissPdbView. The 
structures were aligned with dominated regions using <Fit> column. Each structural differences 
were calculated using <Calculated RMS> at <Fit> column. Average RMSD were calculated for 
each molecule ∑ 𝑅𝑀𝑆(𝑖)
௡
௜ୀଵ 𝑛ൗ  and Mean global RMSD were calculated 
∑ 𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑅𝑀𝑆𝐷(𝑖)௡௜ୀଵ 𝑛ൗ      
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Results 
NMR study of wild type IRAKM-DD is limited.   
The wild type (WT) IRAKM-DD was expressed with maltose binding protein (MBP) as 
a solubility-enhancement tag [31]. When cleaved from MBP, IRAKM-DD rapidly precipitated in 
all buffer conditions explored.  While the larger 42 kDa MBP does not give rise to observed 
peaks in the standard 15N-1H HSQC spectrum, a smaller fusion partner can be selectively 
detected by NMR if tethered to MBP by a sufficiently long linker that allows independent 
rotational diffusion [Reference MBP-ubiquitin paper]. Indeed, the 15N-1H HSQC spectrum of 
180 uM 15N-labeled MBP-IRAKMDD (59 kDa) shows a well-dispersed set of peaks indicative 
of a folded protein of approximately 100 residues that are not observed in the corresponding 
spectrum of 15N-labeled MBP alone (Figure 4.5, overlay of 183 uM fusion, MBP alone).  
Concentration of MBP-IRAKMDD to 480 uM significantly broadened peaks in the 15N-1H 
HSQC spectrum but sequential dilution (330, 230 150, 91 uM) progressively narrowed the peaks, 
suggesting reversible oligomerization. Due to the insolubility of cleaved IRAKM-DD and the 
low fusion protein concentration required for obtaining high quality NMR data, mutagenesis was 
pursued to inhibit oligomerization and enhance solubility of the IRAKM-DD monomer. 
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Figure 4.5. The overlay the 15N-1H HSQC spectrum of 180 uM 15N-labeled MBP-IRAKMDD 
(Red) and 136uM MBP alone (Blue). 
 
Double mutant IRAKM-DD(R56D,Y61E) is highly amenable to NMR studies.   
To visualize potential interface residues in the IRAK-M death domain that could be 
altered to inhibit oligomerization, a homology model was constructed based on the IRAK-2 
death domain in the multiprotein oligomeric Myddosome structure [10]. Substitution of each of 
the four IRAK-2 subunits in the Myddosome structure with an IRAKM-DD homology model 
suggested a key intermolecular salt bridge involving R56 and a potential aromatic network 
involving Y61.  To inhibit these putative interactions through electrostatic repulsion, the R56D 
and Y61E mutations were incorporated into the MBP-IRAKM[1–119] expression vector, 
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yielding a soluble fusion protein. Cleavage of this MBP- IRAKM[1–119:R56D,Y61E] fusion 
protein yielded soluble IRAKM[1–119:R56D,Y61E] monomer, ascertained by size exclusion 
chromatography. The 1H-15N HSQC spectrum of 15N-IRAK-M[1–119:R56D,Y61E] shows 
well-dispersed peaks, indicating that the domain is folded (Figure 4.6). Notably, this spectrum 
overlays peak-for-peak (with only a few exceptions) with the MBP-wild-type IRAKM-DD 
spectrum (Figure 4.7), suggesting that the double mutant retains the native WT fold. The 
backbone (97%) and sidechain (85%) assignments were determined for IRAKM[1–
119:R56D,Y61E] and are deposited at the BioMagResBank (http://www.bmrb.wisc.edu/, 
accession number 26941).  This folded monomeric IRAKM[1–119:R56D,Y61E] mutant was 
used for high resolution structure determination. 
 
Figure 4.6. 2D 1H-15N HSQC spectrum of uniformly 13C/15N labeled IRAKM[1-
119:R56D,Y61E]  
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Figure 4.7. The overlay the 15N-1H HSQC spectrum of 180 uM 15N-labeled MBP-IRAKMDD 
(Red) and 13C/15N labeled IRAKM[1-119:R56D,Y61E] (Green). 
 
NMR structure of the IRAKM death domain.  
The application of standard 15N-separated and 13C-separated three-dimensional 
NOESY experiments, along with chemical shift constraints, enabled the high-resolution NMR 
structure of IRAKM[1-119:R56D,Y61E] to be determined. The structure adopts the canonical 
DD fold, demonstrating that the R56D and Y61E mutations do not disrupt the native fold. This 
structure consists of six α-helices: α1 (P27 – S39), α2 (W46 – L53), α3 (D59 – V67), α4 (T74 – 
S80), α5 (I88 – M98) and α6 (R101 – N109) (Figure 4.8a). These results are also well matched 
with the canonical death domain fold and with predictions from PECAN (Protein energetic 
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conformational analysis from NMR chemical shifts) based on theNMR chemical shift 
assignments (Chapter 3), with the exception of the end of the fourth alpha-helix where PECAN 
predicts that helix 4 ends at residue K84 (Chapter 3 and [BioMagResBank- 
http://www.bmrb.wisc.edu/, with accession number 26941]). The resulting ensemble of lowest 
energy structures have a well defined α-helical core (residues 19-52, 61-110) with a backbone 
RMSD of 0.19 Å.  The overall structure quality was slightly better than the average NMR 
structure in terms of clash score (11) and sidechain outliers (9%), and slightly worse in terms of 
Ramachandran outliers (3%).  
 
Figure 4.8. a. Ribbon diagram of IRAKM[1-119:R56D,Y61E] NMR structure (pdb ID - 5UKE), 
including include N-terminal and C-terminal tails. Black arrows indicate the positions of the N-
terminal and C-terminal tails removing. The model of the IRAKM death domain without N-
terminal and C-terminal tails is used for the docking simulation prediction. IRAKM[18-
113:R56D,Y61E] b. The N-terminal L25 and C-terminal Y110 interaction to hold whole 
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structure.  Figure was generated using Pymol (28) and PowerPoint. 
In addition to the α-helical core, tail regions contribute to the teriary structure of the 
IRAKM DD.  Specifically, although the N- and C-terminal regions (M6 – P26 and Y110 – 
G129, respectively) do not adopt regular secondary structure, residues A15 to P26 form a loop 
that packs against residues in α1, α6, the α4-α5 loop, and Y110 at the beginning of the C-
terminal tail (Figure 4.8b). Residue Y110 is central to this N- to C-terminal tail stabilization, 
with its aromatic ring closely associating with L25 and P26 sidechains that are located right 
before α-helix 1. Interestingly, the IRAK2 subunit in the Myddosome structure also displays this 
N-to-C tail interaction, which in this case is mediated by IRAK2 residue W93 [10]. Moreover, 
Trp in this position is conserved in the IRAK1 sequence but not in IRAK4, suggesting that this 
N-to-C tail interaction is a common feature among the three IRAK family members that are 
directly involved in downstream signaling.  Notably, in this IRAKM DD structure, the nearby 
S115-P116 motif recognized by Pin1 is solvent-exposed in the downstream unstructured part of 
the C-terminal tail, suggesting accessibility for interactions with kinase(s), phosphatase(s), and 
Pin1.   
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Figure 4.9. a. Hydrophobic core 1 involving alpha-helices 1, 2, 4, 5 and 6. b. The hydrophobic 
core 2 involving alpha-helix 2, 3, and 4. c. Sequential residues L49-A50 and L77-L78 that 
belong to different hydrophobic cores. Figure was generated using Pymol [28] and PowerPoint. 
 
The IRAKM death domain tertiary structure is stabilized by two major hydrophobic 
cores. Hydrophobic core 1 primarily involves alpha-helices 1, 5 and 6, but also includes residues 
from alpha-helices 2 and 4 (Figure 4.9a). The residues that are in hydrophobic core 1 are L29, 
L33, V36, L37, L91, L92, L95, A103, I104, I107, L49, and L78. Alpha-helices 2 and 4 
contribute only 1 residue each to hydrophobic core 1 (L49 and L78, respectively). Notably, eight 
out of the twelve residues of hydrophobic core 1 are Leucine.  A smaller, distinct hydrophobic 
core (hydrophobic core 2) involves alpha-helices 2, 3, and 4. The alpha-helices 2, 3, and 4 have 
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fewer residues than alpha-helices 1, 5, and 6, and form a three-helix bundle that is stabilized by 
residues A50, I63, and L77 that form hydrophobic core 2 (Figure 4.9b). 
The two hydrophobic cores are connected by two pairs of sequential residues in which 
the sequential residues belong to different hydrophobic cores (Figure 4.9c). Even though the 
residues L49 and A50 are right next to each other, L49 is directed towards to hydrophobic core 
1, and A50 towards to hydrophobic core 2. Similarly, residues L77 and L78 belong to different 
hydrophobic cores. L77 is part of hydrophobic core 2, and L78 contributes to hydrophobic core 
1. These interesting examples show how the relative orientations of secondary structural 
elements are important for formation of tertiary structural contacts.   
Although the hydrophobic cores 1 and 2 defined above bury the involved hydrophobic 
sidechains on the interior of the IRAKM death domain shielding them from aqueous buffer, 
several additional hydrophobic sidechains are not included. Some of these hydrophobic residues 
are involved in stable interactions (based on observation of NOE cross peaks) between the 
canonical fold and the N- or C-terminal tail regions, or between loops and other regions of the 
structure.  These include interactions that stabilize the L21, L22 and F23 region of the N-
terminal tail, the interactions that stabilize Y110 in the C-terminal tail, and the V67:W46:E64 
interactions that stabilize association between helices 2 and 3.   
Interestingly, while most charged and polar residues are solvent-exposed on the surface 
of the protein, some charged and polar residues are largely buried. For example, E32 and H100 
are both buried in the interface between helices 1 and 6, suggesting a possible mechanism for pH 
sensitivity of fold stability. Similarly, the carboxylate groups of D59 and E76 make close 
approach to each other and are mainly buried between helices 3 and 4.  The close association of 
this group of E76 with the indole ring of H62 suggests a hydrogen bond network that would 
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favor protonation of one or both of these carboxylate groups.  Additionally, K71 and K84, 
which are on loops at opposite ends of helix 4, each have their sidechains nearly fully buried.  
These residues influence the association of helix 4 with helices 1 and 2 at one end (K71) and 
with helices 1 and 5 at the opposite end (K84). The NH3+ group of K71 is within 5 angstroms of 
the carboxylate group of D38, the W46 sidechain, and the backbone carbonyls of D38 and V67, 
providing rationale for its position in the structure.  At the opposite end of the helical bundle, 
the NH3+ group of K84 closely associates with the backbone carbonyl groups of F23 and K86 
but otherwise is surrounded by hydrophobic groups, suggesting compromise in the formation of 
tertiary structure in this region. 
 
Structural Alignment of IRAK-M DD into the Myddosome complex using Magic Fit in 
SwissPDBView  
IRAK family members interact with themselves, with each other or with MyD88 via 
their DDs. The structure of IRAK-M DD was not previously determined, so interactions 
mediated by this domain were not fully studied. It was previously reported that IRAK-M reduces 
IRAK1 phosphorylation, increases IRAK1 association with MyD88, and inhibits formation of 
the downstream IRAK1-TRAF signaling complex40. The structural mechanism by which these 
effects are mediated by IRAK-M are unknown. Since the crystal structure of the MyD88-
IRAK4-IRAK2 death domain complex was solved, the implications of this structure on Toll-like 
receptor signaling cascades was focused on IRAK2-mediated signaling, although it was 
hypothesized that IRAK1 DD could substitute for IRAK2 in this structure [8]. However, no 
structures of the IRAK-1 or IRAK-M death domains had yet been solved experimentally, so 
studies of the IRAK-M interaction with the Myddosome complex were highly speculative [12]. 
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Still missing are the IRAK-1 and IRAK-M components and the mechanism by which IRAK-M 
inhibits TLR-triggered innate immunity signaling. Our newly solved NMR structure of the 
IRAK-M DD now adds a level of confidence to structural alignments and simulations of the 
docking between IRAK-M DD and the different forms of the Myddosome complex.  As an 
initial step in examining interactions of IRAK-M DD in the context of the Myddosome, simple 
structural alignment was used.   
To explore the possibility that the IRAK-M DD can substitute for an IRAK-2 or IRAK1 
DD subunit in the Myddosome complex, the NMR structure of IRAKM[1-119:R56D,Y61E] was 
superimposed onto one of the IRAK2 DD subunits in the Myddosome complex using the Magic 
Fit structural alignment function in SwissPdbView [29], and the contact surfaces formed 
between IRAK-M DD and the surrounding IRAK-2 DD and IRAK-4 DD subunits were 
examined. In the resulting structural model, it is immediately apparent that the ordered N-
terminal tail region of IRAK-M DD is placed toward the interior of the Myddosome complex, 
resulting in steric clashing between this N-terminal segment (missing in the IRAK2 DD 
subunits) and the surrounding subunits.  This suggests that the N-terminal tail must be displaced 
from its anchored position against the IRAK-M surface in order for IRAK-M to adopt the 
canonical DD subunit orientation observed in the Myddosome complex.  This intriguingly 
implicates the N-terminal tail as a conformational switch, wherein it is folded against the IRAK-
M surface in the monomer and is released from this surface upon docking. Other than the N-
terminal tail clashing, the contact surfaces between IRAK-M DD and the surrounding IRAK-2 
DD and IRAK-4 DD subunits do not show any obvious additional steric clashes or unfavorable 
electrostatic interactions. This motivated us to perform rigorous docking simulations without 
inclusion of the N-terminal tail region.   
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Docking simulations predict selective formation of IRAK-M/IRAK1 heterotetramer in the 
context of the Myddosome complex 
To investigate possible interactions that might facilitate IRAK-M regulation of IRAK1-
mediated signaling, docking simulations were performed using a Myddosome-based model 
containing IRAK1 DD in place of IRAK2 DD subunits using the program ClusPro40-43.  Prior 
to docking simulations, the mutated IRAK-M residues (R56D and Y61E) were restored in silico 
to their wild type identities using the Mutate tool in SwissPdbView, and IRAK-M residues 1-17 
and 114-119 were deleted from the IRAK-M structure file to generate IRAK-M[18-113]. IRAK-
M[18-113] was docked with a modified Myddosome composed of six MyD88, four IRAK4, 
three IRAK1 DD subunits, and an empty IRAK1 DD subunit space. For each of the four scoring 
schemes applied, the resulting ten models (representing highly populated clusters of low energy 
complexes) included IRAK-M DD docked into the empty subunit position in the canonical 
orientation. These docked models revealed favorable IRAK-M DD interactions with both IRAK1 
DD and IRAK4 DD (Figure 4.10, Figure 4.11a,b).  Docking simulations were also performed 
for the double-mutant IRAK-M to assess the impact of the R56D and Y61E mutations.  The 
docking score for MyD88-IRAK4-IRAK1 and wt-IRAKM DD was slightly lower energy (-873.8 
at center, and -1069.6 at lowest energy, Figure 4.10a) than the docking score for MyD88-
IRAK4-IRAK1 and IRAKM DD(R56D, Y61E) (-872 at center, and -949.5 at lowest energy, 
Figure 4.10b).  However, both wild-type and double-mutant forms yielded IRAK-M DD 
subunits docked in the canonical orientation. 
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Figure 4.10. A ClusPro generated model of IRAK-M DD docked into a modified Myddosome 
oligomer containing three IRAK1 DD subunits in the L, M and N positions in the 3MOP 
structure. Blue: six MyD88 DD subunits, Green: Four IRAK4 DD subunits, Cyan: three IRAK1 
DD homology model subunits, Yellow: docked NMR structure of the IRAK-M DD. a. The 
docking simulation between MyD88-IRAK4-IRAK1 and wt-IRAKM DD by ClusPro. b. The 
docking simulation between by MyD88-IRAK4-IRAK1 and IRAKM DD: R56D, Y61E by 
ClusPro. 
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Figure 4.11. a. Interaction between IRAK-M DD and IRAK1 DD from Figure 4.10. Cyan: 
IRAK1 DDs, Yellow: IRAK-M DD. B. The aromatic residues interaction between IRAK-M DD 
and IRAK4 DD from Figure 4.10. Green: IRAK4 DDs, Yellow: IRAK-M DD 
 
For comparison, IRAK-M was also docked with a Myddosome complex composed of 
six MyD88, four IRAK4, three IRAK2 DD subunits and an empty IRAK2 DD subunit space. In 
contrast to the above findings for IRAK-M docking into an IRAK1-containing Myddosome, 
these simulations for an IRAK2-containing Myddosome yielded no models with IRAK-M 
docked into the empty subunit position in the canonical orientation. Repulsion between IRAK-M 
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E51 and IRAK2 D14 and absence of a favorable IRAK-M D38 interaction with IRAK1 R61 
(S47 in IRAK2) could explain this result.  Moreover, docking simulations using IRAK-M 
DD(R56D, Y61E) also yielded no docked models with the canonical orientation.  This 
comparison suggests distinct mechanisms for interaction of IRAK-M with the Myddosome, 
depending on whether it contains IRAK2 or IRAK1. 
For further comparison, we investigated docking of the IRAK-M DD monomer into a 
Myddosome model containing three IRAK-M DD subunits in place of three IRAK2 DD subunits 
and leaving an empty subunit space as above. The ClusPro docking simulation provided the best 
107 combinations between IRAKM DD and the MyD88-IRAK4-IRAKM complex, but none 
showed the docked IRAK-M subunit in the canonical orientation. These results further support 
the prediction that formation of an IRAK-M/IRAK1 heterotetramer is highly selective, and 
occurs more favorably than and IRAK-M/IRAK2 heterotetramer or an IRAK-M homotetramer. 
 
Simulations show IRAK-M DD tetramer fails to substitute for IRAK2 DD tetramer in the 
MyD88-IRAK4 complex 
Based on the findings that IRAK-M is crucial for NF-κB activation in IRAK1/IRAK2 
double knockout mice and that the IRAK-M DD recruits IRAK-M to the TLR-MyD88-IRAK4 
complex in response to low dose LPS leading to MEKK3-dependent NFκB activation [12], an 
additional question of interest is whether an IRAKM DD tetramer can substitute for the IRAK2 
tetramer in the Myddosome complex.  To address this question, docking of an IRAK-M 
tetramer to the assembled MyD88-IRAK4 portion of the Myddosome was simulated.  The 
MyD88-IRAK4 complex was generated by deleting the four IRAK2 subunits from the 3MOP 
pdb structure file, and an IRAK-M DD tetramer model was constructed using Swiss-PbdViewer 
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and Pymol by superposition with the IRAK2 subunits in the Myddosome structure. These two 
complexes were submitted for docking simulations to ClusPro.  The results showed that the 
IRAK-M DD tetramer associates in many different ways with the MyD88-IRAK4 assembly, but 
displays a preference for associating with the MyD88 DD end rather than the IRAK2 DD end of 
the complex (Figure 4.12). Additional evidence that IRAK-M does not show binding to the 
IRAK4 platform in the Myddosome was obtained by docking an IRAK-M DD monomer to the 
MyD88-IRAK4 assembly. In the best 24 balanced models, none show IRAK-M DD monomer 
bound to the IRAK4 DD surface used for association with the IRAK2 tetramer (Figure 4.13). 
These results suggest that an IRAK-M tetramer fails to substitute for the IRAK2 DD tetramer.  
However, its preference for interacting with the MyD88 surface raises the possibility that a 
putative IRAK-M tetramer might compete with MyD88 association with the TIR (toll-IL-1 
receptor) domain of the Toll-like receptor. Together, these simulations suggest that the crucial 
role of IRAK-M in the IRAK1/IRAK2 double knockout mouse is not mediated by simple 
tetramer substitution in the Myddosome complex. 
As a positive control for tetramer docking to the MyD88-IRAK4 complex, ClusPro 
docking simulations were also performed for the IRAK2 tetramer obtained from the 3MOP pdb 
structure file. Indeed, this IRAK2 tetramer docked to the MyD88-IRAK4 assembly in the same 
orientation as found in the experimentally determined Myddosome structure (3MOP pdb 
structure file), providing important validation for the use of the ClusPro docking program for 
predicting tetramer association with the MyD88-IRAK4 assembly.   
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Figure 4.12. IRAKM DD tetramer randomly bound to the surface of the MyD88-IRAK4 
complex. The figures are from the Balanced model of the ClusPro results. Cyans: MyD88-
IRAK4 complex, Red: IRAKM DD tetramer. Black arrow indicates MyD88 Position 
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Figure 4.13. IRAKM DD monomer randomly bound to the surface of the MyD88-IRAK4 
complex. The figures are from the Balanced model of the ClusPro results. Cyans: MyD88-
IRAK4 complex, Red: IRAKM DD: W.T. Black arrow indicates MyD88 Position. 
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Docking simulations predict specific IRAK-M DD interactions with IRAK2 DD subunits in 
the Myddosome complex 
To further investigate potential mechanisms by which IRAK-M might impart the known 
effects on IRAK2-mediated NFkB signaling [12], we investigated IRAK-M DD interactions with 
IRAK2 DD subunits in the context of the full Myddosome complex (MyD88-IRAK4-IRAK2 
DDs). The IRAK-M[18-113] monomer and tetramer forms were separately docked with the 
Myddosome complex using ClusPro.  
The resulting docked complexes of the IRAK-M monomer with the Myddosome shows 
preferred interaction with the IRAK2 bottom surface (Figure 4.14).  IRAK-M residues W79 and 
W81 are consistently involved in the observed interactions with the IRAK2 subunits. The 
docking score for each resulting complex is very similar (Figure 4.14 A, B, C). The docking 
scores for A are -965 at the center and -1093.4 at the lowest energy. The docking scores for B are 
-952.5 at the center and -1103.9 at the lowest energy. The docking scores for C are -927.9 at the 
center and -1175.2 at the lowest energy. All of three of positions of docking formation have 
similar energy favorability.  
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Figure 4.14. The docking simulation of the IRAKM DD monomer to the Myddosome complex. 
Blue: six of MyD88 DD, Green: four of IRAK4 DD, Red: four of IRAK2 DD, Yellow: IRAKM 
DD: W.T. A, B, C. The IRAKM DD dock under the MyD88-IRAK4-IRAK2 DD Complex in 
different positions.  
 
Docking simulations for association of the IRAK-M tetramer with the Myddosome yield 
three major classes of assembly, two of which show IRAK-M DD subunits interacting similarly 
with IRAK2 as elucidated in the monomer IRAK-M docking simulations. Specifically, the 
IRAK-M tetramer utilizes either two (Figure 4.15A) or one (Figure 4.15B) of its IRAK-M DD 
subunits to dock with the IRAK2 bottom surface.  In both of these classes, the orientation of the 
interacting IRAK-M DD subunit(s) is the same as that of the IRAK-M DD monomer docked to 
the Myddosome. In contrast, the third class is non-specific interaction of IRAKM DD tetramer in 
various orientations with the side of IRAK2 or IRAK4 DDs.  
A B C 
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Figure 4.15. The docking simulation of the IRAKM DD tetramer to the Myddosome complex. 
Blue: six of MyD88 DD, Green: four of IRAK4 DD, Red: four of IRAK2 DD, Yellow: four of 
IRAKM DD: W.T. A, B, C. The IRAKM DD tetramer dock to the MyD88-IRAK4-IRAK2 DD 
Complex in different positions.  
 
These docking simulations show that an individual IRAK-M DD subunit does favorably 
interact with the IRAK2 DD surface displayed in the Myddosome structure.  This is in contrast 
to the docking simulations of the IRAK-M monomer to the IRAK4 DD surface presented above, 
A B 
C 
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where no preferred interactions were observed with the comparable IRAK4 surface.  Together, 
these results suggest that a possible mechanism for IRAK-M regulation of IRAK2-mediated 
signaling might be through direct binding of IRAK-M to IRAK2 DD subunits assembled in the 
Myddosome. 
 
Assessment of the impact of IRAK-M DD structural variation on the docking results  
The NMR structure determination of IRAK-M[1-119:R56D,Y61E] consists of 20 lowest 
energy models that are consistent with the NMR constraints, where model 13 is the overall 
representative, medioid model. Across this ensemble of models, the backbone root mean square 
deviation (RMSD) is 0.19 Å, indicating excellent agreement of backbone fold across the 20 
models.  The sidechains, especially those that are surface-exposed, are much less constrained so 
the ensemble of structures represents a wide range of surface sidechain conformations.  
Although the ClusPro docking process includes sidechain rearrangements and minor backbone 
adjustments, an important question is whether different models from the NMR determined 
ensemble will yield significantly different docked structures.    
To address the impact of sidechain conformational variability on the resulting docked 
structures, three different models from the NMR ensemble (model 1, model 13, and model 20), 
with an average all-atom RMSD among them of 0.95 Å, were chosen for comparative docking 
studies.  Again, prior to docking simulations, the mutated IRAK-M residues (R56D and Y61E) 
were restored in silico to their wild type identities and IRAK-M residues 1-17 and 114-119 were 
deleted to generate IRAKM[18-113] for each model. These substitutions did not change the all-
atom RMSD among the three models (0.95 Å). From the docking studies presented above, the 
most specific docking result was the case where the IRAKM[18-113] monomer was docked with 
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with a modified Myddosome composed of six MyD88, four IRAK4, three IRAK1 DD subunits, 
and an empty IRAK1 DD subunit space. Therefore, this case was chosen to evaluate the 
variation of docked models resulting from variation of IRAK-M DD models used for docking. 
Each of the three IRAK-M DD models was docked to the MyD88-IRAK4-IRAK1 DD 
complex for examination of the effect of side chain orientation. Notably, all three cases yielded 
IRAK-M DD docked in the canonical DD orientation into the empty subunit position. To 
evaluate structural differences between these docked IRAK-M DD structures resulting for 
models 1, 13, and 20, a representative docked complex for each case was selected, and these 
three docked models were structurally aligned using Magic Fit in SwissPdbView.  This 
structural alignment is dominated by the invariant regions across the three docked models, 
namely the MyD88-IRAK4-IRAK1 DD portion of the Myddosome. From these aligned 
complexes, the IRAKM[18-113] residues were selected and saved as separate PDB files while 
preserving their positions relative to the Myddosome assembly. The RMSD of each combination, 
{1,13}, {1,20}, {13,20}, {13,1}, {20,1}, {20,13}, was then calculated, along with the mean 
RMSD across these combinations (Table 4.2). The mean all-atom RMSD is 2.78 Å.   
To evaluate how much the IRAK-M DD structure was adjusted during the docking 
process, the extracted IRAK-M DD structures (post docking) were structurally aligned using 
Magic Fit.  The resulting RMSD (1.74 Å) is larger than the pre-docking RMSD of models 1, 13 
and 20 (0.95 Å), indicating that the docking process adjusted the structural models somewhat.  
These results indicate that the RMSD between the docked structures (2.78 Å) arises from 
both orientational differences relative to the Myddosome complex as well as adjustments to the 
IRAK-M DD structure during the docking process.  However, the three models from the NMR 
ensemble yielded qualitatively the same results, with similarly docked IRAK-M DD in the 
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canonical orientation in the IRAK1-containing Myddosome.  These comparisons provide 
confidence in the predicted formation of an IRAK-M/IRAK1 heterotetramer in the Myddosome 
complex that is mediated by their DDs. 
 
 
Table 4.2. All-atom RMSD of Myddosome-docked IRAK-M DD models 1, 13 and 20  
   Avg_RMSD 1st_WT 13th_WT 20th_WT 
1st_WT 2.98   2.95 3.01 
13th_WT 2.66 2.95   2.37 
20th_WT 2.69 3.01 2.37   
Mean global RMSD 2.77666667       
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Table 4.3. RMSD of IRAKM DD models 1, 13 and 20 before docking to the Myddosome 
  Avg_RMSD 1st_WT 13th_WT 20th_WT 
1st_WT 0.81   0.80 0.81 
13th_WT 1.02 0.80   1.24 
20th_WT 1.03 0.81 1.24   
Mean global RMSD 0.95       
 
Table 4.4. RMSD of the extracted and Magic Fit aligned IRAKM DD after docking to the 
Myddosome 
  Avg_RMSD 1st_WT 13th_WT 20th_WT 
1st_WT 1.65   1.75 1.55 
13th_WT 1.84 1.75   1.93 
20th_WT 1.74 1.55 1.93   
Mean global RMSD 1.74       
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Discussion 
The NMR structure of IRAK-M DD represents the first solution NMR structure of a 
human IRAK family member death domain.  This structure was made possible by site-directed 
mutation of two surface-exposed amino acid residues that successfully inhibited aggregation 
while preserving the folded state.  The domain structure is stabilized by hydrophobic packing 
that can be parsed into two hydrophobic cores that mediate the association of six alpha helices. 
Additionally, the N-terminal and C-terminal regions of IRAKM-DD participate in hydrophobic 
interactions with each other and with the alpha helical fold, which is a feature that is also 
observed in IRAK2 and is sequence-wise conserved in IRAK1 but not in IRAK4. Extensive 
interactions anchor the N-terminal tail region to the surface of the helical fold, imparting order to 
residues A15 – P26.  Just downstream of the ordered C-terminal region, the S115-P116 motif 
recognized by Pin1 is solvent-exposed in the NMR structure of IRAK-M DD, suggesting 
accessibility for protein-protein interactions. Although this solution NMR-determined structure 
indeed adopts the expected canonical death domain fold, the details of this structure, including 
the elucidation of interactions involving the N- and C-termianal tail regions, have enabled 
docking simulation studies that provide important insights regarding the varied roles of IRAK-M 
in innate immunity signaling. 
 Overall, the docking simulations that were performed using the newly determined NMR 
structure of the IRAK-M DD indicate that the IRAK-M DD interacts favorably with the MyD88-
IRAK4-IRAK1 Myddosome complex, where the IRAK-M DD can replace an IRAK-1 DD 
subunit and form favorable interaction interfaces with both neighboring IRAK-1 DD subunits 
and with the juxtaposed IRAK-4 DD surface.  Importantly, formation of this IRAK1/IRAK-M 
heterotetramer requires the release of the IRAK-M N-terminal tail region from the domain 
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surface, suggesting that the IRAK-M N-terminal tail region functions as a conformational switch. 
In contrast, unfavorable interactions prevent the comparable insertion of the IRAK-M DD into 
the MyD88-IRAK4-IRAK2 Myddosome complex, and formation of an IRAK-M DD tetramer is 
not favored.  However, an individual IRAK-M DD subunit does favorably interact with the 
IRAK-2 DD surface displayed in the Myddosome structure.  What insights do these docking 
simulations provide regarding the mechanisms by which IRAK-M facilitates its various and 
sometimes opposite effects in innate immunity signaling? 
IRAK-M is known to inhibit IRAK1-mediated NF-kB signaling, and has been shown to 
reduce IRAK1 phosphorylation, increase IRAK1 association with MyD88, and inhibit formation 
of the downstream IRAK1-TRAF signaling complex40. Our docking simulations performed 
using the NMR structure of IRAK-M DD suggest that the Myddosome framework allows 
formation of an IRAK1-IRAK-M hetero-tetramer and suggest a model by which IRAK1 can 
phosphorylate IRAK-M S115-P upon stimulation (Figure 4.16 a-d). In this proposed model, a 
single IRAK1 molecule cannot hyper-phosphorylate its own UD, rather the IRAK1 UD can only 
be hyper-phosphorylated by its next-neighbor IRAK1 KD due to spatial constraints (Figure 
4.16a). Our docking simulations suggest that the IRAK-M DD might replace every other IRAK-
1 DD subunit in the Myddosome complex, thereby forming a heterotetramer with IRAK1 (Figure 
4.16b). This alternating IRAK1/IRAK-M structure might prevent the IRAK1 kinase domain 
(KD) from hyper-phosphorylating the next-neighbor IRAK1 UD, prevent IRAK1 release from 
the Myddosome, and suppress IRAK1-mediated inflammation (Figure 4.16c).  
Through our own collaborative work, we have shown that when cells and mice are 
stimulated with asthma-inducing IL-33, IRAK-M and Pin1 play essential roles in the induction 
of inflammation.  Specifically, upon IL-33 stimulation, IRAK-M is phosphorylated by IRAK1 
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at S115, Pin1 is activated, and Pin1 binding and isomerization of the pS115-P motif increases 
IRAK-M nuclear translocation and protein stability that correlates with increased expression of a 
set of pro-inflammatroy cytokines [15]. In our proposed IRAK1-IRAK-M hetero-tetramer 
containing Myddosome model, Pin1 binding to the solvent exposed IRAK-M pS115P motif and 
subsequent isomerization of this motif could displace the C-terminal region of IRAK-M DD, 
thereby disrupting the Y105-mediated N-to-C interaction and inducing IRAK-M dissociation 
from the Myddosome (Figure 4.16d) for downstream IRAK-M dependent signaling. 
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Figure 4.16. Proposed model for IRAK-M and PIN1 regulation of IRAK1 mediated immunity 
signaling. a. IRAK1 homotetramer assembled on the Myddosome is able to achieve full 
hyperphosphorylation through each IRAK1 undefined domain (UD) being phosphorylated by 
neighboring IRAK1 kinase domains (KDs). b. In the presence of IRAK-M, heterotetrameric 
IRAK-M/IRAK1 assembles on the Myddosome where IRAK-M DD replaces every-other 
IRAK1 DD subunit, preventing further IRAK1 hyper-phosphorylation and inhibiting IRAK1 
release from the Myddosome thereby suppressing IRAK1-mediated inflammation. c. IRAK1 KD 
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phosphorylates S110 in next-neighbor IRAK-M. d. Binding of PIN1 to IRAK-M pS110P (IRAK-
M phosphorylated at residue S110) and subsequent isomerization induces release of IRAK-M 
from the Myddosome for downstream PIN1- and IRAK-M dependent signaling. 
 
This proposed model, based on our NMR structure and subsequent docking simulations, 
suggests how formation of an IRAK1-IRAK-M heterotetramer on the Myddosome could prevent 
IRAK1 activation, possibly explaining the known effects of IRAK-M on IRAK1 
phosphorylation, signaling and association with MyD8840.  This model also provides a 
mechanism by which IRAK1 could phoshorylate IRAK-M on S115P to generate a Pin1 
recognition site, and that Pin1 binding and isomerization of the pS115-P motif in IRAK-M could 
promote IRAK-M release from Myddosome complex, leading to IRAK-M dependent signaling 
[15].  
 IRAK-M is also known to play an inhibitory role in TLR-induced IRAK2 mediated 
signaling, and was predicted to do so through formation of an IRAK-M DD tetramer that binds 
to the IRAK2 tetramer platform in the full Myddosome complex [12]. This prediction was made 
using an IRAK-M DD homology model. Our ClusPro-generated simulation of docking between 
the Myddosome (MyD88-IRAK4-IRAK2 DD) complex and our NMR structure of IRAK-M DD 
is interesting, because it suggests an alternative mode of interaction between IRAK-M DD and 
the Myddosome whereby one or two IRAK-M DD bind to the IRAK2 DD platform. In fact, our 
docking simulations showed no resulting docked models as proposed by Zhou et al. [12]. Base 
on our docking results, IRAK-M DD might bind to the Myddosme complex at the IRAK2 
surface as a monomer or dimer rather than as a tetramer. In this manner, IRAK-M DD could 
suppress IRAK2-mediated signaling by preventing IRAK2 from participating in downstream 
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interactions.  
 In conclusion, the solution NMR structure of IRAK-M DD has yielded several important 
insights regarding the structural mechanisms by which IRAK-M carries out its varied functions 
in innate immunity signaling pathways.  While the IRAK-M N-terminal tail region is ordered 
and packs against the domain surface in the monomer state, this extended interface must be 
disrupted in order for IRAK-M to form a heterotetramer with IRAK1 in the context of the 
Myddosome complex.  This implicates the N-terminal tail of IRAK-M as a conformational 
switch that regulates IRAK-M interactions with the Myddosome.  Formation of the 
IRAK1/IRAK-M heterotetramer is specific, and provides a distinct mechanism by which IRAK-
M might facilitate its suppression of IRAK1-mediated signaling.  On the other hand, IRAK-M 
suppression of IRAK2-mediated signaling appears to utilize a very different mechanism, 
whereby IRAK-M binds to the solvent-exposed IRAK2 teteramer surface.  These predictions 
generated by simulated docking using our NMR-determined IRAK-M DD structure offer models 
that motivate further cell and molecular biology investigations to more completely understand 
the structural mechanisms of IRAK-M in the regulation of innate immunity signaling. 
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Appendix 1 
 
Plasmid Information 
 
Plasmid Information for pMAL-c2X 
 
Plasmid Name: pMAL-c2X 
Parent Plasmid: pMAL-c2X 
Detail of Construction: 
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pMAL-c2X vector contains tac promoter and lacI, thus protein expression level can be 
controlled by IPTG concentration. pMAL-c2X vector is Ampicillin resistance. MBP (Maltose 
Binding Protein) is located at the N-terminal, and inserted DNA will be located at the C-
terminal. The restriction site NdeI is at N-terminal of MBP.  Restriction sites SacI, EcoRI, 
BamHI, XbaI, SalI, OstI and HindII are located at C-terminal of MBP. 
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Plasmid Information for pMAL-c2X_IRAKM[1-119:R56D,Y61D] 
 
Plasmid Name: pMAL-c2X_IRAKM[1-119:R56D,Y61D] 
Parent Plasmid: pMAL-c2X 
Detail of Construction: 
PCR amplification from clone hIRAKM (IRAK3, NCBI: NM_007199.2) using the primers. 
Forward with BamHI: 5’ act gat gga tcc atg gcg ggg aac tgt ggg gcc cgc ggc gcg 3’  
Backward with HindIII: 5’ gac agt aag ctt tca acc ttc ctg ata act ctt ctc tga agg 3’ 
PCR product was ligated into the vector pMAL-c2X using sticky ends. The BamHI and HindIII 
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restriction sites were used to cut the PCR insert and pMAL-c2X plasmid in order to obtain the 
pMAL-c2X_IRAKM[1-119]. The R56D and Y61D mutations were achieved using this vector.  
Forward : 5’ agc agc tgg ctg gat gtt gat cat att gaa aag gat gta gac caa ggt aaa agt g 3’ 
Backward : 5’ c act ttt acc ttg gtc tac atc ctt ttc aat atg atc aac atc cag cca gct gct 3’ 
PCR amplification and mutagenesis were performed by BIO RAD-iProof High-Fidelity DNA 
Polymerase to generate expression plasmid pMAL-c2X _IRAKM[1-119:R56D,Y61D]. 
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Plasmid Information for pMAL-c2X_IRAKM[1-119:R56D,Y61E] 
 
Plasmid Name: pMAL-c2X_IRAKM[1-119:R56D,Y61E] 
Parent Plasmid: pMAL-c2X 
Detail of Construction: 
The R56D and Y61E mutations were achieved using pMAL-c2X_IRAKM[1-119:R56D,Y61D] 
vector. 
Forward : 5’ gtt gat cat att gaa aag gag gta gac caa ggt aaa agt gg 3’ 
Backward : 5’ cc act ttt acc ttg gtc tac ctc ctt ttc aat atg atc aac 3’ 
Mutagenesis was performed by BIO-RAD-iProof High-Fidelity DNA Polymerase to generate 
expression plasmid pMAL-c2X_IRAKM[1-119:R56D,Y61E]. 
